WO2015157557A1 - Procédés de diagnostic du cancer du pancréas et procédés associés - Google Patents

Procédés de diagnostic du cancer du pancréas et procédés associés Download PDF

Info

Publication number
WO2015157557A1
WO2015157557A1 PCT/US2015/025179 US2015025179W WO2015157557A1 WO 2015157557 A1 WO2015157557 A1 WO 2015157557A1 US 2015025179 W US2015025179 W US 2015025179W WO 2015157557 A1 WO2015157557 A1 WO 2015157557A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
patient
pancreatic cancer
panel
biomarker
Prior art date
Application number
PCT/US2015/025179
Other languages
English (en)
Inventor
Karri Lynn BALLARD
Ralph Leon MCDADE
Michael Douglas SPAIN
Samuel Thomas LABRIE
James Preston MAPES
Michael Graham Walker
Jing Shi
Matt FIRPO
Sean MULVIHILL
Original Assignee
Myriad Rbm, Inc.
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Rbm, Inc., University Of Utah Research Foundation filed Critical Myriad Rbm, Inc.
Publication of WO2015157557A1 publication Critical patent/WO2015157557A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Definitions

  • the invention generally relates to diagnostic methods and particularly to diagnostic methods utilizing pancreatic cancer biomarkers.
  • Pancreatic cancer is the fourth leading cause of cancer death in the United States. Rebecca Siegel et al, Cancer Statistics, 2013, CA: A Cancer Journal for Clinicians 1 1 (2013). Pancreatic cancer has a 5-year survival rate of only 5%. Because the disease is largely asymptomatic at early stages, early detection of pancreatic cancer is rare, and over 85% of pancreatic cancer patients have tumors that cannot be surgically resected at the time of diagnosis. However, resection of pancreatic tumors at early stages dramatically improves survival rates, up to a 5-year survival of 75% when tumors are less than 10mm at diagnosis and resection. Therefore, early detection of pancreatic cancer in a patient may increase the likelihood of successful treatment and survival.
  • the present disclosure includes methods of screening for pancreatic cancer, wherein the methods comprise determining from a biological sample of a patient the levels of a panel of biomarkers, comparing the level of each biomarker to threshold levels for each biomarker and determining the likelihood the patient has pancreatic cancer.
  • the biomarkers are selected from Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • the biomarkers selected consist of both positive and negative biomarkers.
  • the methods include determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker and conducting endoscopic ultrasonography or magnetic resonance
  • the methods include conducting endoscopic ultrasonography or magnetic resonance
  • cholangiopancreatography if the patient has at least 4 biomarkers that have either a level above the threshold level for that particular positive biomarkers or a level below the threshold level for that particular negative biomarkers.
  • the present disclosure also includes methods of screening a biological sample, wherein the method includes obtaining a biological sample, determining in the biological sample the levels of a panel of biomarkers selected from a panel of biomarkers, comparing the level of each biomarker to threshold levels for each biomarker, and determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the panel comprises any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • the methods include screening patients with a first-degree relative diagnosed with pancreatic cancer.
  • the methods include screening a sample from a patient with a mutation in a BRCA2, PALB2, p l 6, STK1 1 , MLH 1 , MSH2, MSH6, PMS2, or EPCAM gene.
  • the methods include screening patient with a diagnosis of hereditary non- polyposis colorectal cancer.
  • the methods include screening patient with a diagnosis of Lynch syndrome, Peutz-Jeghers syndrome, acute
  • pancreatitis chronic pancreatitis, or recent onset diabetes.
  • the present disclosure also includes methods of diagnosing pancreatic cancer, wherein the methods comprise determining from a biological sample of a patient a level of a panel of biomarkers. The methods may further comprise comparing the level of the panel of biomarkers to threshold levels for each biomarker. The methods may further comprise determining the presence or absence of the panel of biomarkers that have a level either above a threshold level for each particular positive biomarker or below a threshold level for each particular negative biomarker, wherein the presence of the panel of such biomarkers indicates a likelihood of pancreatic cancer.
  • the biomarkers are at least 3 biomarkers selected from of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • methods of diagnosing pancreatic cancer further comprise determining the number of family members of the patient diagnosed with pancreatic cancer and determining the degree of relationship to the patient of any such family member; determining the presence or absence of a mutation in a BRCA2, PALB2, pl6, STK1 1, MLH1, MSH2, MSH6, PMS2, or EPCAM gene of the patient, or determining whether the patient has hereditary non-polyposis colorectal cancer.
  • methods of diagnosing pancreatic cancer further comprise determining from a biological sample of the patient the level of each biomarker of a panel of biomarkers for pancreatic cancer, wherein the panel comprises positive biomarkers, negative biomarkers, or both, and comparing the level of each biomarker to threshold levels for each biomarker.
  • methods of diagnosing pancreatic cancer further comprise determining whether the patient has or is symptomatic of Lynch syndrome, chronic pancreatitis, recent onset diabetes, acute pancreatitis, or Peutz-Jeghers syndrome.
  • methods of diagnosing pancreatic cancer further comprise determining the number of patient biomarkers that have either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker; determining the magnitude of the difference in level for each biomarker of the patient that is either above a threshold level for that particular positive biomarker or below a threshold level for that particular negative biomarker; and calculating the probability of early- stage pancreatic cancer based on at least (i) the number of family members of the patient diagnosed with pancreatic cancer, (ii) the degree of relationship to the patient of any such family member, (iii) the presence or absence of a mutation in a BRCA2, PALB2, pl6, STK11, MLH1, MSH2, MSH6, PMS2, or EPCAM gene or whether the patient has hereditary non-polyposis colorectal cancer, (iv) the number of patient biomarkers that have either a level above the threshold level for each particular positive biomarkers
  • methods of diagnosing pancreatic cancer further comprise determining the existence of pancreatic cancer by computed tomography (CT), somatostatin receptor scintigraphy (SRS), positron emission tomography (PET), ultrasonography (ultrasound), endoscopic retrograde cholangiopancreatography (ERCP), angiography, or biopsy.
  • CT computed tomography
  • SRS somatostatin receptor scintigraphy
  • PET positron emission tomography
  • ultrasonography ultrasonography
  • ERCP endoscopic retrograde cholangiopancreatography
  • angiography or biopsy.
  • the methods further include treating the patient for pancreatic cancer.
  • the patient is treated by surgical resection of the tumor, chemotherapy, radiation therapy, ablative techniques, or some combination thereof.
  • the present disclosure also includes determining the probability of early stage pancreatic cancer in a patient, wherein the method comprises determining from a biological sample of a patient a level of a panel of biomarkers.
  • the methods may further comprise comparing the level of the panel of biomarkers to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of the panel of biomarkers that have a level either above a threshold level for each particular positive biomarker or below a threshold level for each particular negative biomarker, wherein the presence of the panel of such biomarkers indicates a likelihood of pancreatic cancer.
  • the biomarkers are selected from any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in
  • the methods include screening patients with a first-degree relative diagnosed with pancreatic cancer. In some embodiments, the methods include screening patient with a mutation in a BRCA2, PALB2, p l 6, STK1 1 , MLH 1 , MSH2, MSH6, PMS2, or EPCAM gene. In some embodiments, the methods include screening patient with a diagnosis of hereditary non-polyposis colorectal cancer. In some embodiments, the methods include screening patient with a diagnosis of Lynch syndrome, Peutz-Jeghers syndrome, acute pancreatitis, chronic pancreatitis, or recent onset diabetes.
  • the present disclosure also includes computer-assisted methods of determining the probability of a patient having early-stage pancreatic cancer, wherein the methods comprise providing biomarker information from a biomarker information database module on a data processing device, wherein the biomarker information comprises threshold level information for each biomarker of a panel of biomarkers, wherein the panel of biomarkers comprises positive biomarkers, negative biomarkers, or both, wherein a level above a threshold level for positive biomarkers is indicative of the presence of pancreatic cancer in a patient and a level below a threshold level for negative biomarkers is indicative of the presence of pancreatic cancer in a patient.
  • the methods may further comprise providing patient information from a patient information database module on a data processing device, wherein the patient information comprises biomarker level information for the patient.
  • the methods may further comprise comparing with a comparison module on a data processing device biomarker information and patient information.
  • patient information may include family history, and the patient's medical history.
  • the methods may further comprise determining with an evaluation module on a data processing device operably connected to the comparison module a number of patient biomarkers with either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods may further comprise determining with a calculation module on a data processing device operably connected to the evaluation module a probability of early-stage pancreatic cancer based on the above-determined number.
  • the methods may further comprise displaying a graphical representation of the patient's probability of early-stage pancreatic cancer.
  • the present disclosure also includes methods of assessing the likelihood of pancreatic cancer in a patient, wherein the methods comprise determining from a biological sample of a patient the levels of a panel of biomarkers. The methods may further comprise comparing the levels for each biomarker measured in a control subject. The methods may further comprise comparing the levels of biomarkers in the patient and in the control subject and determining the likelihood of pancreatic cancer in the subject.
  • the biomarkers are selected from any Panel A through L.
  • the biological sample is blood or plasma.
  • the control subjects are healthy, or have a diagnosis of other cancer or diabetes.
  • the subject has one first degree relative with a pancreatic cancer diagnosis.
  • the subject has a mutation in one of the pl6, BRCA2, PALB2, or STK11 genes.
  • the subject is symptomatic of or diagnosed with Lynch syndrome, chronic pancreatitis, acute pancreatitis, diabetes, or Peutz-Jeghers syndrome.
  • the biomarkers are selected by performing statistical analysis and selecting biomarkers with a t-test p-value equal to or less than 0.05, an ANOVA p-value equal to or less than 0.05, a Wilcoxon rank sum p-value equal to or less than 0.05, or a Kruskal-Wallis p-value equal to or less than 0.05.
  • a model or algorithm is created which incorporates the expression level of biomarkers and calculates a probability that an individual suffers from pancreatic cancer.
  • the likelihood of pancreatic cancer in the patient is confirmed by biopsy, Computed tomography (CT) scan, Somatostatin
  • SRS Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ultrasonography ultrasound
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography Angiography
  • the patient is treated with surgical resection, chemotherapy, radiation therapy, or ablative techniques.
  • the present disclosure also includes methods of treating a patient wherein the methods comprise measuring the levels of a panel of biomarkers in a patient, comparing the levels of the panel of biomarkers in the patient with a threshold level for each biomarker, and treating the patient for pancreatic cancer.
  • the methods further comprise correlating a level of biomarker above the threshold for a positive biomarker or below the threshold for a negative biomarker in any of said panel of biomarkers to an increased likelihood of pancreatic cancer, or correlating a level of biomarker below the threshold for a positive biomarker or above the threshold for a negative biomarker in any of said panel of biomarkers to no increased likelihood of pancreatic cancer, and recommending, prescribing, or administering a treatment or care to the patient for pancreatic cancer.
  • the biomarkers are selected from any panel A through L.
  • the panel of biomarkers is at least three biomarkers from Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • pancreatic cancer in the patient is confirmed by biopsy, Computed tomography (CT) scan, Somatostatin Receptor Scintigraphy (SRS), Positron Emission Tomography (PET) scan, ultrasonography (ultrasound), Endoscopic Retrograde
  • ERCP Cholangiopancreatography
  • Angiography Angiography
  • the patient is treated with surgical resection, chemotherapy, radiation therapy, or ablative techniques.
  • the present disclosure also includes methods of diagnosing pancreatic cancer wherein the methods comprise reacting a biological sample from the subject with at least three reagents, each one of which specifically binds to a different biomarker in a panel and determining whether the selected markers is over expressed or under expressed in the sample, thereby providing a diagnosis for pancreatic cancer in the subject.
  • over or under expression is determined by comparing expression level to a predetermined threshold.
  • the panel of biomarkers is determined by comparing the levels in the patient to a control group, the control group can consist of healthy age-matched individuals, individuals diagnosed with early stage pancreatic cancer, late stage pancreatic cancer, other cancers, diabetes, or a combination thereof.
  • the subject has been diagnosed with or is symptomatic of Lynch syndrome, chronic pancreatitis, new onset diabetes, acute pancreatitis, or Peutz-Jeghers syndrome; has at least one first degree relative with a pancreatic cancer diagnosis; has a germ line germ-line mutation in at least one of the p i 6, BRCA2, PALB2, or STKl 1 genes, or some combination thereof.
  • determining an expression level comprises determining protein expression, or RNA expression. In some embodiments, determining an expression level comprises determining protein concentration in a biological sample.
  • the present disclosure also includes methods of screening a biological sample, wherein the methods comprise obtaining a biological sample and determining a level in the biological sample of at least 3, 4, or 5 biomarkers in any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of each biomarker to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods comprise determining a level in the biological sample of each biomarker of the panel.
  • the present disclosure also includes methods of screening a biological sample, wherein the methods comprise detecting the level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14 in a biological sample of an individual identified as having (i) a first-degree relative diagnosed with pancreatic cancer, (ii) a mutation in a BRCA2, PALB2, pl6, STKl 1, MLH1, MSH2, MSH6, PMS2, or EPCAM gene, (iii) a diagnosis of hereditary non-polyposis colorectal cancer, (iv) chronic pancreatitis, (v) diabetes, or (vi) a combination of (i)-(v).
  • the present disclosure also includes methods of screening a biological sample, wherein the methods comprise detecting in a biological sample of an individual identified as having (i) a first-degree relative diagnosed with pancreatic cancer, (ii) a mutation in a BRCA2, PALB2, pl6, STKl 1, MLH1, MSH2, MSH6, PMS2, or EPCAM gene, (iii) a diagnosis of hereditary non-polyposis colorectal cancer, or (iv) a combination of (i)-(iii), the level of at least 4 biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • the present disclosure also includes a kit for detecting the presence of early-stage pancreatic cancer in a patient, the kit comprising reagents useful, sufficient, or necessary for determining the level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Figure 1 illustrates a system for performing computer-assisted methods of determining the probability of a patient having early-stage pancreatic cancer.
  • Figure 2 shows sample boxplots for the biomarker analysis performed on Panel A in Example 1.
  • Figure 3 shows the mean AUCs calculated in Example 1 for
  • Figure 4 shows the mean AUCs calculated in Example 1 for
  • Figure 5 shows the mean AUCs calculated in Example 1 for
  • Figure 6 shows the mean AUCs calculated in Example 1 for
  • Figure 7 shows the mean AUCs calculated in Example 1 for
  • Figure 8 shows the mean AUCs calculated in Example 1 for
  • Figure 9 shows the mean AUCs calculated in Example 1 for differentiation of PDAC from ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers, excluding CA 19-9.
  • Figure 10 shows the mean AUCs calculated in Example 1 for differentiation of CON from ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers, excluding CA 19-9.
  • Figure 1 1 shows a heatmap depicting Pair-wise Pearson correlation coefficients among significant analytes for Example 1.
  • Figure 12 shows boxplots for the biomarker analysis performed on
  • Figure 13 shows the mean AUCs calculated in Example 2 for differentiation of PDAC from CON and ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 14 shows the mean AUCs calculated in Example 2 for differentiation of PDAC from CON from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 15 shows the mean AUCs calculated in Example 2 for differentiation of PDAC from ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 16 shows the mean AUCs calculated in Example 2 for differentiation of CON from ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 17 shows the mean AUCs calculate in Example 2 for differentiation of late stage PDAC from CON and ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 18 shows the mean AUCs calculate in Example 2 for differentiation of late stage PDAC from CON and ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 19 shows the mean AUCs calculate in Example 2 for differentiation of late stage PDAC from CON and ChPT from 100 multivariate analysis bootstraps using lasso, random forest, log it, or boosting, and the best 2 to 15 biomarkers.
  • Figure 20 shows the mean AUCs calculate in Example 2 for
  • Figure 21 shows the mean AUCs calculate in Example 2 for
  • Figure 22 shows the mean AUCs calculate in Example 2 for
  • Figure 23 shows a heatmap of pair- wise Pearson correlation coefficients among significant analytes for Example 2.
  • Figure 24 shows a cluster dendrogram of Hierarchical clustering of PDAC samples sets from Example 1 and Example 2.
  • one aspect of the present invention provides a method for screening patients.
  • the method includes at least the following steps: (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (2) determining the likelihood that the individual has pancreatic cancer based at least in part on the levels of the panel of biomarkers in the sample.
  • the methods may be used to determine the individual has early stage pancreatic cancer.
  • the present invention provides a method for diagnosing pancreatic cancer, which comprises (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (2) diagnosing the patient with pancreatic cancer based at least in part on the levels of the panel of biomarkers in the sample.
  • the methods may be used to diagnose early stage pancreatic cancer.
  • the methods may be used to classify individuals with pancreatic cancer from individuals with other diseases such as other cancers, diabetes, Peutz-Jeghers syndrome, lynch syndrome, chronic pancreatitis, or acute pancreatitis.
  • the present invention provides a method for treating pancreatic cancer, which comprises (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (2) treating the patient for pancreatic cancer.
  • the methods may be used to treat early stage pancreatic cancer.
  • the present invention provides a method for screening patients.
  • the method includes at least the following steps: (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (2) determining the likelihood that the patient has pancreatitis based at least in part on the levels of the panel of biomarkers in the sample.
  • the present invention provides a method for diagnosing pancreatitis, which comprises (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (2) diagnosing the patient with pancreatitis based at least in part on the levels of the panel of biomarkers in the sample.
  • the methods may be used to diagnose acute or chronic pancreatitis.
  • the methods may be used to classify patients with pancreatitis from patients with other diseases such as pancreatic cancer, other cancers, diabetes, Peutz-Jeghers syndrome, or Lynch syndrome.
  • the present invention provides a method for treating pancreatitis, which comprises (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels A - F; and (2) treating the patient for pancreatitis.
  • the methods may be used to treat acute pancreatitis. In other embodiments, the methods may be used to treat chronic pancreatitis.
  • the present invention provides a method for
  • the method includes at least the following steps: (1) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers comprising at least three biomarkers in any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (2) diagnosing the patient with either pancreatitis or pancreatic cancer based at least in part on the levels of the panel of biomarkers in the sample.
  • the methods may also include: (3) differentially treating the patient for either pancreatitis or pancreatic cancer based at least in part on the diagnosis of step (2).
  • the present invention provides for a computer program that uses biomarker levels to assesses the probability of a patient having pancreatic cancer or pancreatitis, comprising providing biomarker information from a biomarker information database module on a data processing device, wherein the biomarker information comprises threshold level information for each biomarker of a panel of biomarkers, wherein the panel of biomarkers comprises positive biomarkers, negative biomarkers, or both, wherein a level above a threshold level for positive biomarkers is indicative of the presence of pancreatic cancer or pancreatitis in a patient and a level below a threshold level for negative biomarkers is indicative of the presence of pancreatic cancer or pancreatitis in a patient.
  • the computer program assesses the probability of a patient having early stage pancreatic cancer. In other embodiments, the computer program assesses the probability of a patient having a differential diagnosis of either pancreatitis or pancreatic cancer. In some embodiments, a statistically generated model or algorithm is used to assess the likelihood that a patient suffers from pancreatic cancer or pancreatitis.
  • the invention provides a system for measuring the levels of biomarkers in a sample, comprising (1) a first computer program for receiving test biomarker data on the panel of biomarkers and (2) a second computer program for comparing the levels of biomarkers to one or more reference levels.
  • the system comprises a computer program for determining the likelihood a patient has pancreatic cancer based at least in part on the comparison of the levels of biomarkers in the sample with said one or more reference levels.
  • the system comprises a computer program for determining a differential diagnosis of either pancreatitis or pancreatic cancer for a patient based at least in part on the comparison of the levels of biomarkers in the sample with said one or more reference levels.
  • a statistically generated model is used. In other
  • the invention provides methods for combining the biomarker analysis as described above with analysis of other cancer risk factors, such as the patient's family and/or personal history of cancer, genetic analysis, or the patient's health history.
  • the invention provides a method for determining whether a patient has pancreatic cancer, which comprises (1) evaluating the patient's personal and family history risk factors for pancreatic cancer (2) classifying the patient as at risk for pancreatic cancer (3) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers selected from any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (4) determining the likelihood that the patient has pancreatic cancer based on the patient's risk factors and the levels of the panel of biomarkers in the sample.
  • the invention provides a method for differentially diagnosing whether a patient has pancreatic cancer or pancreatitis, which comprises (1) evaluating the patient's personal and family history risk factors for pancreatic cancer or pancreatitis (2) classifying the patient as at risk for pancreatic cancer or pancreatitis (3) measuring the levels of a panel of biomarkers in a sample taken from a patient, said panel of biomarkers selected from any of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; and (4) determining a differential diagnosis of either pancreatic cancer or pancreatitis for the patient based on the patient's personal and family history risk factors and the levels of the panel of biomarkers in the sample.
  • Personal risk factors may include, age, history of smoking, cancer diagnosis, new-onset diabetes diagnosis, diabetes diagnosis, Lynch syndrome diagnosis, Peutz- Jeghers syndrome diagnosis, chronic pancreatitis diagnosis, acute pancreatitis diagnosis, or genetic mutations in BRCA2, PALB2, pl6, STK1 1, MLH1, MSH2, MSH6, PMS2, or EPCAM.
  • Family history risk factors can include a relative with pancreatic cancers, a relative with early onset cancer, a relative with multiple primary cancers, etc.
  • a step of correlating a particular assay or analysis result or output e.g., increased or decreased level of individual biomarkers in a panel of biomarkers compared to thresholds
  • some likelihood e.g., increased, not increased, decreased, etc.
  • some clinical feature e.g., pancreatic cancer, pancreatitis, etc.
  • an alternative aspect of the invention may involve, in addition to or instead of a correlating step, one or more of the following steps: (a) concluding that the patient has or does not have the clinical feature based at least in part on the assay or analysis result; (b) communicating that the patient has or does not have the clinical feature based at least in part on the assay or analysis result; (c) treating the patient based at least in part on the assay or analysis result; or (d) referring the patient for additional screening.
  • the methods include evaluating the likelihood of pancreatic cancer in a patient at risk for developing pancreatic cancer.
  • the patient has at least one first degree relative with a pancreatic cancer diagnosis.
  • the individual has been diagnosed with or is symptomatic of Lynch syndrome.
  • the individual has been diagnosed with or is symptomatic of chronic pancreatitis.
  • the individual has been diagnosed with or is symptomatic of acute pancreatitis.
  • the individual has been recently diagnosed with or is symptomatic of diabetes.
  • the individual has been diagnosed with or is symptomatic of Peutz-Jeghers syndrome.
  • the individual has a mutation in a BRCA2 gene.
  • the individual has a mutation in a PALB2 gene. In some embodiments, the individual has a mutation in a pi 6 gene. In some embodiments, the individual has a mutation in a STK1 1 gene. In some embodiments, the individual has a mutation in a MLH1 gene. In some embodiments, the individual has a mutation in a MSH2 gene. In some embodiments, the individual has a mutation in a MSH6 gene. In some embodiments, the individual has a mutation in a PMS2 gene. In some embodiments, the individual has a mutation in an EPCAM gene. In some embodiments, the individual has any combination of the above indications.
  • the methods include evaluating the likelihood of pancreatitis in a patient at risk for developing pancreatitis.
  • the patient has a personal history of chronic pancreatitis.
  • the patient has episodes of abdominal pain.
  • the patient has a personal history of heavy alcohol use.
  • the patient has a hereditary disorder of the pancreas or hereditary pancreatitis.
  • the patient has cystic fibrosis.
  • the patient has hypercalcemia, hyperlipidemia and/or hypertriglyceridemia.
  • the patient has certain autoimmune disorders that cause the patient to be more likely to develop pancreatitis.
  • the patient has any combination of the above indications. In other embodiments, the patient has a family history that causes the patient to be more likely to have any combination of the above indications. [0061] In some embodiments, the methods include evaluating the likelihood of developing pancreatic cancer in a patient with pancreatitis. In some embodiments, the patient has been diagnosed with acute pancreatitis. In some embodiments, the patient has been diagnosed with chronic pancreatitis.
  • the patient has risk factors for developing pancreatitis including any one or more of: history of chronic pancreatitis, episodes of abdominal pain, personal history of heavy alcohol use, hereditary disorder of the pancreas, hereditary pancreatitis, cystic fibrosis, hypercalcemia, hyperlipidemia,
  • the patient has risk factors for developing pancreatic cancer including any one or more of: a first degree relative with pancreatic cancer, a diagnosis or symptoms of Lynch syndrome, a diagnosis of new-onset diabetes, a diagnosis of diabetes, and/or a diagnosis or symptoms of Peutz-Jeghers syndrome.
  • a patient has at least one mutation in any one or more of the following genes: BRCA2, PALB2, pl6, STK11, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
  • the patient has any combination of the above indications.
  • the methods, systems and kits of the invention will comprise measuring a panel of biomarkers.
  • the panel of biomarkers analyzed in the methods, systems and kits of the invention will comprise at least some of the biomarkers listed in Panels A-L.
  • the panel of biomarkers comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 75, 80, 85, 90, 95, or 100 biomarkers listed in Panels A-L.
  • the biomarkers chosen from Panels A-L comprise at least some percentage, e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, of the panel of biomarkers to be analyzed.
  • the panel of biomarkers may be selected by comparing the levels of the biomarkers in a control group with the level of biomarkers in a group with early stage pancreatic cancer.
  • the biomarkers may be selected by comparing the levels of biomarkers in control group with the level of biomarkers in a group of individuals with late stage pancreatic cancer.
  • the control group may consist of healthy age matched individuals.
  • the control group may further consist of individuals with other cancers.
  • the control group may further consist of individuals with diabetes.
  • biomarkers may be selected by performing statistical analysis on the measured levels of biomarkers in a group of individuals with pancreatic cancer compared to controls. Biomarkers may be selected based on their t-test p- value, where said value is equal to or less than 0.05. In some embodiments biomarkers may be selected based on their ANOVA p-value, where said value is equal to or less than 0.05. In some embodiments biomarkers may be further selected based on their Wilcoxon p-value, where said value is equal to or less than 0.05. In some embodiments biomarkers may be further selected based on their Kruskal-Wallis p-value, where said value is equal to or less than 0.05. In some embodiments biomarkers may be selected based on their q- value, where said value is equal to or less than 0.05. In some embodiments biomarkers may be selected based on their area under the receiver operating characteristic curve ("AUC") value.
  • AUC receiver operating characteristic curve
  • the biomarkers are selected from Neuropilin-1,
  • Peptidase D Peptidase D
  • NGAL Neutrophil Gelatinase-Associated Lipocalin
  • DPPIV Dipetidyl Peptidase IV
  • Cancer Antigen 19-9 CA 19-9
  • Complement Component Clq Receptor ClqRl
  • Interleukin-6 Receptor Subunit Beta IL-6R beta
  • Fatty Acid-Binding Protein Liver Fatty Acid-Binding Protein Liver (FABP liver), Lumican, Cathespin D
  • Lactoferrin LTF
  • Cartilage Oligomeric Matrix Protein COMP
  • Squamous Cell Carcinoma Antigen- 1 SCCA-1
  • Cadherin-1 Squamous Cell Carcinoma Antigen- 1
  • SCFR Monokine Induced by Gamma Interferon
  • VEGF-C Vascular Endothelial Growth Factor C
  • Osteopontin Antileukopronteinase
  • SP-D Pulmonary Surfactant-
  • PEPD PEPD, NGAL, DPPIV, CA 19-9, FABP liver, IL-6R beta, ClqRl, VEGF-C, Lumican,
  • tPA Tissue Type Plasminogen Activator
  • TIE-2 EGF Homology Domains 2
  • the biomarkers are selected from Neuropilin-1,
  • PEPD Carcrinoembryonic Antigen-Related Cell Adhesion Molecule 6 (CEACAM6), Cancer Antigen 9 (CA-9), FABP liver, ClqRl, Oseoponitin, TATI, CEACAM1, IL-6, Lumican, uPAR, Galectin-3, SCFR, CA-125, B Cell-Activating Factor (BAFF), OPG, Tumor Necrosis Factor Receptor 1 (TNF Rl), VEGF-C, MIG, IL-2 receptor alpha, ALP, IGFBP5, COMP, YKL-40, Cadherein-1, Midkine, SDF-1, Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1), Prostasin, SCCA-1, LTF, Leptin, Interleukin- 18 Binding Protein (IL-18bp), TIE-2, Vascular Endothelial Growth Factor (VEGF), TSP4,
  • Hepatocyte Growth Factor HGF
  • Collagen IV Collagen IV
  • 6Ckine TIMP-2
  • MIP-3 beta Macrophage Inflammatory Protein 3 beta
  • TNF-C Tenascin-C
  • VEGF- D Vascular Endothelial Growth Factor D
  • G6PI Glucose-6-Phosphate Isomerase
  • S100-A6 S100-A6
  • Tetranectin Tetranectin
  • the biomarkers are selected from Neuropilin-1,
  • PEPD DPPIV, CA 19-9, NGAL, CA-9, CEACAM6, galectin-3, cathespin-D, FABP liver, lumican, BAFF, TATI, OPG, uPAR, IL-6R beta, IL-6, ClqRl, CA-125, SCFR, osetopontin, VEGF, CEACAM1, TNF RI, YKL-40, SDF-1, midkine, leptin, VEGF-C, IL-2 receptor alpha, MIG, IGFBP5, prostasin, LTF, cystatin B, SCCA-1, IL-18bp, CEA, HE4, COMP, hespin, G6PI, CTSB, TIE-2, aldose reductase, VEGFR-1, HGF, Cadherin-1, SP-D, ALP, IGFBP4, TIMP-2, decorin, maspin, , Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3), PSAT, MIP
  • biomarkers are measured by using Enzyme-Linked
  • ELISA Immunosorbent Assay
  • LCMS liquid chromatography mass spectrometry
  • SELDI-TOF surface enhanced laser desorption ionization time of flight mass spectrometry
  • 2-DE two-dimension gel electrophoresis
  • biomarkers are measured using bead-based multiplex immune assays.
  • the bead-based multiplex immune assays further comprise combining Luminex technology with automated liquid handling.
  • the methods includes detection of blood proteins.
  • the methods include using small sample volumes.
  • the sample volume is as low as lOul.
  • the methods include measuring biomarkers in a dynamic range of fg/ml to mg/ml.
  • biomarkers are measured using a multiplexed assay.
  • the multiplexed assay further comprises a microsphere-based assay.
  • multiplex assays are performed in a single reaction vessel.
  • multiplex assays are performed by combining optical classification schemes, biochemical assays, flow cytometry, and advanced digital signal processing hardware and software. In some embodiments as many as 100 multiplex assays are performed in a single reaction vessle.
  • the multiplex assay inculdes analyte-specific microspheres labeled with a unique flourescent signature.
  • microbeads are labled with red flourecent dye.
  • microbeads are labeled with far red flourescent dye.
  • microbeads are lableled with varying intensitiy of dye.
  • the multiplex assay inculdes an assay specific capture reagent that is covalently conjugted to a set of unique microspheres.
  • conjugation occurs with carbodimide chemistry.
  • conjugation occurs with carboxyl functional groups on the surmace of the microsphers.
  • conjugation occurs with primary amines in the capture agent.
  • the assay specific capture reagent is an antibody.
  • the assay specific capture reagent is an antigen, receptor, peptide or enzyme substrate.
  • the assay-specific capture reagent on each individual microsphere binds the analyte of interest.
  • a biotinylated detecting reagent is added to the assay.
  • the biotinylated detecting reagent is an antibody, antigen or ligand.
  • the biotinlyated detecting moledule is assay-specific.
  • a streptavidin-labeled floursecent molecule is added to the assay.
  • the streptavidin-labeled floursecent molecule is phycoerythrin.
  • the assay kinetics are near solution-phase.
  • the multiplex assay is washed to remove unbound detecting reagents.
  • the multiplex reaction is passed through an analyzer comprising laser beams.
  • the analyzer uses hydrodynamic focusing to pass microspheres through the analzyer in single file.
  • the indivudal mircosphers pass through at least one excitation beams.
  • miscrosphere size is measured.
  • microsphere size is determined by measuring 90-degree light scatter.
  • microsphere size is deteremined by passing the mirospheres through a red diode, 633 nm, laser.
  • miscosphere aggregates are removed from analysis.
  • the encoded floursecent signaure of the mincrobead is analyzed.
  • the flouresent signature is determined by passing the microspheres through a red diode laser.
  • the flouresent signature is measured using avalance photodiodes.
  • miscrosphere flourescence is measured.
  • microsphere flouresence is measured by passing the microspheres through a green diode, 532 nm, laser.
  • a flourescent reporter signal is genereated in proportion to the analyte concentration.
  • the flourescens is measured using a photomultiplier tube.
  • At least 100 microspheres from each analyte set are analyzed.
  • the median value of the analyte-specific flourescent is measured.
  • analyte flourecemce is calibrated using internal controls of known quantity.
  • the patient is human.
  • the biological sample is taken from a patient or individual.
  • the sample is blood. In some embodiments the sample from is plasma. In some embodiments the sample from the patient may include urine, blood, plasma, serum, buffy coat, saliva or buccal swabs. [0080] In some embodiments, the sample is serum, plasma or blood.
  • the biological sample is stored and/or shipped at room temperature with or without stabilizers. In some embodiments, the biological sample is stored and/or shipped frozen. In some embodiments, the biological sample is stored and/or shipped chilled. In some embodiments, serum, plasma or whole blood arebe dried on a material for storage and or shipping. In a related embodiment, the biological sample is eluted from the storage material when ready to be tested at the testing site.
  • the methods of the invention generally involve measuring the levels of a panel of biomarkers described herein. With modern techniques, it is often possible to measure the levels of tens or hundreds of biomarkers. Once such a global assay has been performed, one may then informatically analyze one or more subsets of biomarkers (panels, or sub-panels of biomarkers). After measuring the levels of tens or hundreds of biomarkers in a sample, for example, one may analyze (e.g., informatically) the levels of a panel or sub-panel of test biomarkers comprising primarily biomarkers in any of Panels A-L according to the present invention.
  • a specific targeted panel of biomarkers is selected and only those biomarkers are measured in the biological sample.
  • those specific panels comprise at least 3 biomarkers selected from of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14
  • the levels of the biomarkers in the individual are compared to a threshold or a reference standard.
  • the threshold for each biomarker is determined by measuring the levels of the biomarker in a healthy age- and sex- matched individual or group of healthy age matched individuals.
  • the threshold for each biomarker is determined by measuring the levels of the biomarker in an individual or group of individuals with a known early stage pancreatic cancer diagnosis.
  • the threshold for each biomarker is determined by measuring the levels of the biomarker in an individual or group of individuals with a known late stage pancreatic cancer diagnosis.
  • the threshold for each biomarker is further determined by measuring the levels of the biomarker in an individual or group of individual with a cancer diagnosis other than pancreatic cancer. In some embodiments, the threshold for each biomarker is further determined by measuring the levels of the biomarker in an individual or group of individuals diagnosed with diabetes. In some embodiments, the threshold for each biomarker is further determined by measuring the levels of the biomarker in an individual or group of individuals diagnosed with acute pancreatitis. In some embodiments, the threshold for each biomarker is further determined by measuring the levels of the biomarker in an individual or group of individuals diagnosed with chronic pancreatitis. In some embodiments, the threshold for each biomarker is further determined by measuring the levels of the biomarker in an individual or group of individuals diagnosed with acute pancreatitis and chronic pancreatitis.
  • the levels of the biomarkers in the individual are compared to levels measured in one or more control group(s).
  • the control group consists of healthy, age-matched individuals.
  • the control group consists of individuals with an early stage pancreatic cancer diagnosis.
  • the control group consists of individuals with a late stage pancreatic cancer diagnosis.
  • the control group consists of individuals with a cancer diagnosis other than pancreatic cancer.
  • the control group consists of individuals with diabetes.
  • the control group consists of individuals with acute pancreatitis.
  • the control group consists of individuals with chronic pancreatitis.
  • the control group consists of individuals with acute and chronic pancreatitis.
  • the determination of the likelihood an individual has pancreatic cancer is based on determining the levels of biomarkers in the individual's sample are significantly different than those measured in the control group. In some embodiments, the determination of the likelihood an individual has pancreatic cancer is based on the magnitude of the difference between the levels of biomarkers in the individual's sample and the levels of biomarkers in the control sample. In some embodiments, the determination of the likelihood an individual has pancreatic cancer is based on determining the levels of biomarkers in the individual's sample are elevated when compared to a control group. In some embodiments, the determination of the likelihood an individual has pancreatic cancer is based on determining the levels of biomarkers in the individual's sample are decreased when compared to a control group.
  • the determination of the likelihood an individual has pancreatic cancer is based on determining the levels of biomarkers in the individual's sample are above or below the threshold level. In some embodiments, the determination of the likelihood an individual has pancreatic cancer is based on the magnitude of the difference between the levels of biomarkers in the individual's sample and the threshold. [0087] In some embodiments the levels of biomarkers in the individuals sample indicate early stage pancreatic cancer. In some embodiments the levels of biomarkers indicate stage 2 pancreatic cancer. In some embodiments the levels of biomarkers indicated stage 3 pancreatic cancer.
  • the determination of the likelihood that an individual has chronic pancreatitis is based on determining that the levels of biomarkers in the patient's sample are significantly different than those measured in the control group. In some embodiments, the determination of the likelihood that a patient has pancreatitis is based on the magnitude of the difference between the levels of biomarkers in the patient's sample and the levels of biomarkers in the control sample. In some embodiments, the determination of the likelihood that a patient has pancreatitis is based on determining the levels of biomarkers in the patient's sample are elevated when compared to a control group. In some embodiments, the determination of the likelihood that a patient has pancreatitis is based on determining the levels of biomarkers in the patient's sample are decreased when compared to a control group.
  • the determination of the likelihood that a patient has pancreatitis is based on determining that the levels of biomarkers in the patient's sample are above or below the threshold level. In some embodiments, the determination of the likelihood that an individual has pancreatic cancer is based on the magnitude of the difference between the levels of biomarkers in the individual's sample and the threshold. In some embodiments the levels of biomarkers in the individuals sample indicate acute pancreatitis. In some embodiments the levels of biomarkers indicate chronic pancreatitis.
  • comparing a biomarker in a sample to a control or reference comprises generating a statistical model to determine the likelihood an individual suffers from pancreatic cancer or chronic pancreatitis.
  • the statistical tools of lasso, random forest, logistic regression, or boosting are used to generate a statistical model to differentiate pancreatic cancer or chronic pancreatitis or control populations with a given sensitivity and specificity.
  • a linear model is used to generate a score which indicates an individual's probability of having pancreatic cancer or chronic pancreatitis.
  • the expression levels measured in a sample are used to derive or calculate a value or score, as described above.
  • This value may be derived solely from expression levels or optionally derived from a combination of the expression value scores with other components (e.g., clinical staging, etc.) to give a potentially more comprehensive value/score.
  • related embodiments involve deriving or calculating a value or score from the measured status, where that score is based on a statistical analysis of diseased and control populations as described above.
  • multiple scores e.g., expression test value and clinical parameters, such as clinical staging
  • Single component e.g., biomarker
  • combined test scores for a particular patient can be compared to single component or combined scores for reference populations, with differences between test and reference scores being correlated to or indicative of some clinical feature.
  • this disclosure provides methods comprising (1) obtaining the measured expression levels of a panel of genes in a sample from the patient, (2) calculating a test value from these measured expression levels, (3) comparing said test value to a reference value calculated from measured expression levels of the panel of genes in a reference population of patients, and (4)(a) correlating a test value greater than the reference value to a diagnosis of pancreatic cancer, (4)(b) correlating a test value equal to or less than the reference value to a diagnosis of chronic pancreatitis or (4)(c) correlating a test value equal to or less than the reference value to a benign diagnosis.
  • test value is calculated by averaging the measured expression of the panel genes (as discussed below). In some embodiments the test value is calculated by weighting each of the panel of genes in a particular way.
  • the methods comprise determining from a biological sample of a patient a level of a panel of biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of the panel of biomarkers to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of the panel of biomarkers that have a level either above a threshold level for each particular positive biomarker or below a threshold level for each particular negative biomarker.
  • the levels of the panel of biomarkers indicates a likelihood of pancreatic cancer.
  • the levels of the panel of biomarkers indicates a likelihood of chronic pancreatitis
  • the levels of the panel of biomarkers indicates a patient with chronic pancreatitis is likely to have pancreatic cancer.
  • the methods may further comprise determining the level of the biomarkers in a control group.
  • the methods may further comprise comparing the levels of the panel of biomarkers in the patient with the levels measured in the control group.
  • the methods may further comprise determining the levels of the panel of biomarkers in the patient are different than the levels measured in the control group.
  • the different levels of such biomarkers indicates a likelihood of pancreatic cancer.
  • the different levels of such biomarkers indicates a likelihood of chronic pancreatitis.
  • the control group will include healthy, age-matched individuals.
  • the control group may further include individuals with diabetes or other cancers.
  • the methods may further comprise determining the threshold level of the panel of biomarkers by measuring the levels of the panel of biomarkers in individuals known to have early stage pancreatic cancer. In some embodiments the threshold level may be further determined by measuring the levels of biomarkers in individuals known to have late stage pancreatic cancer. In some embodiments the threshold levels may be further determined by measuring the levels of the biomarkers in individuals with diabetes or other cancers. In some embodiments the methods may further comprise determining the threshold level of the panel of biomarkers by measuring the levels of the panel of biomarkers in individuals known to have chronic pancreatitis.
  • the methods may further comprise determining the levels of the panel of biomarkers in a group of individuals with a diagnosis of pancreatic cancer, early stage pancreatic cancer, or late stage pancreatic cancer.
  • the methods further comprise determining from the biological sample of the patient the level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • the methods further comprise determining the number of family members of the patient diagnosed with pancreatic cancer and determining the degree of relationship to the patient of any such family member.
  • the methods further comprise determining the presence or absence of a mutation in a BRCA2, PALB2, p l 6, STK1 1 , MLH 1 , MSH2, MSH6, PMS2, or EPCAM gene of the patient, or determining whether the patient has hereditary non-polyposis colorectal cancer or a history of diabetes or chronic pancreatitis.
  • the above methods can be used to indicate an individual has or has a high probability of having pancreatic cancer, thus in some embodiments the results of the biomarker analysis will indicate further testing. In some embodiments, further testing may confirm a diagnosis of pancreatic cancer.
  • the biomarker analysis may be confirmed by Computed Tomography (CT) scan.
  • the biomarker analysis may be confirmed by Somatostatin Receptor Scintigraphy (SRS).
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • the biomarker analysis may be confirmed by ultrasonography
  • the biomarker analysis may be confirmed by Endoscopic Retrograde Cholangiopancreatography (ERCP). In some embodiments the biomarker analysis may be confirmed by Angiography. In some embodiments the biomarker analysis may be confirmed by biopsy. In some embodiments the biomarker analysis may be confirmed by surgery.
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography Angiography
  • biopsy biopsy
  • biomarker analysis may be confirmed by surgery.
  • the above methods can be used to diagnose a patient with pancreatitis based in part on the analysis of the biomarker assay.
  • the diagnosis of pancreatitis will indicate further testing to confirm a diagnosis of pancreatitis.
  • further testing may include one or more of the following: abdominal ultrasound, computerized tomography scan (CT scan), endoscopic ultrasound (EUS), magnetic resonance cholangiopancreatography (MRCP), therapeutic endoscopic retrograde cholangiopancreatography (ERCP).
  • CT scan computerized tomography scan
  • EUS endoscopic ultrasound
  • MRCP magnetic resonance cholangiopancreatography
  • ERCP therapeutic endoscopic retrograde cholangiopancreatography
  • the biomarker analysis may be confirmed by biopsy.
  • the biomarker analysis may be confirmed by surgery.
  • the above methods can be used to differentially diagnose a patient with either pancreatitis or pancreatic cancer.
  • the differential diagnosis of either pancreatitis or pancreatic cancer will indicate further testing to either confirm a diagnosis of pancreatitis or confirm a diagnosis of pancreatic cancer.
  • the further testing to confirm a diagnosis of pancreatitis may include any of the confirmatory pancreatitis testing listed above.
  • the further testing to confirm a diagnosis of pancreatic cancer may include any of the confirmatory pancreatic cancer testing listed above.
  • the results of the biomarker analysis will indicate treatment of pancreatic cancer.
  • the biomarker analysis indicates treatment of pancreatic cancer by chemotherapy.
  • the biomarker analysis indicates treatment of pancreatic cancer by surgical resection.
  • the biomarker analysis indicates treatment of pancreatic cancer by radiation therapy.
  • the biomarker analysis indicates treatment of pancreatic cancer by ablative techniques.
  • the biomarker analysis indicates treatment of pancreatic cancer by some combination of chemotherapy, radiation therapy, ablative techniques and/or surgical resection.
  • the results of the biomarker analysis will indicate treatment of pancreatitis.
  • the biomarker analysis indicates treatment of pancreatitis by one or more of the following techniques: hospitalization of intravenous fluids, antibiotics, pain medications, and/or nasogastric feeding.
  • treatment of pancreatitis may include therapeutic endoscopic retrograde cholangiopancreatography (ERCP) to perform sphincterotomy, gallstone removal, stent placement, and/or balloon dilatation.
  • ERCP therapeutic endoscopic retrograde cholangiopancreatography
  • treatment of pancreatitis may include synthetic pancreatic enzymes, avoidance of alcohol, treatment of diabetes and/or specialized diet.
  • treatment of pancreatitis may involve surgical removal of all or part of the pancreas.
  • the differential diagnosis will indicate a differential treatment of either pancreatitis or pancreatic cancer.
  • the treatment can include any of the disclosed treatments indicated for pancreatic cancer.
  • the treatment can include any of the disclosed treatments indicated for pancreatitis.
  • the treatment may include subsequent, follow-up biomarker analysis to monitor for the development of pancreatic cancer.
  • the levels of one or more biomarkers or the levels of a specific panel of biomarkers in a sample are compared to a reference standard ("reference standard” or “reference level”) in order to direct treatment decisions.
  • the reference standard used for any embodiment disclosed herein may comprise average, mean, or median levels of the one or more biomarkers or the levels of the specific panel of biomarkers in a control population.
  • the reference standard may additionally comprise cutoff values or any other statistical attribute of the control population, such as a standard deviations from the mean levels of the one or more biomarkers or the levels of the specific panel of biomarkers.
  • comparing the level of the one or more biomarkers is performed using a cutoff value. In related embodiments, if the level of the one or more biomarkers is greater than the cutoff value, the individual may be diagnosed as having, or being at risk of developing pancreatic cancer or chronic pancreatitis. In other distinct embodiments, if the level of the one or more biomarkers is less than the cutoff value, the individual may be diagnosed as having, or being at risk of developing pancreatic cancer or chronic pancreatitis. Cutoff values may be determined by statistical analysis of the control population to determine which levels represent a high likelihood that an individual does or does not belong to the control population. In some embodiments, comparing the level of the one or more biomarkers is performed using other statistical methods. In related embodiments, comparing comprises logistic or linear regression. In some embodiments, comparing the level of the one or more biomarkers is performed by generating a multivariate model. In other embodiments, comparing comprises computing an odds ratio.
  • control population may comprise healthy individuals, individuals with chronic pancreatitis, individuals with pancreatic cancer, or a mixed population of individuals with chronic pancreatitis, pancreatic cancer or both.
  • individuals with levels of one or more biomarkers or levels of a specific panel of biomarkers greater than the reference levels would be more likely to have pancreatic cancer or chronic pancreatitis. Therefore, an individual presenting with levels of the one or more biomarkers or levels of the specific panel of biomarkers greater than the reference standard would be a candidate for treatment for pancreatic cancer, treatment for pancreatitis, or with more aggressive treatment for pancreatic cancer or pancreatitis On the other hand, an individual presenting with levels of the one or more biomarkers or levels of the specific panel of biomarkers less than or equal to the reference standard would be less likely to have pancreatic cancer and therefore be a candidate for no treatment for pancreatic cancer, no treatment for pancreatitis, delayed treatment for pancreatic cancer, delayed treatment for pancreatitis or less aggressive treatment for pancreatic canceror pancreatitis.
  • individuals with levels of one or more biomarkers or levels of a specific panel of biomarkers less than the reference levels would be more likely to have pancreatic cancer or chronic pancreatitis. Therefore, an individual presenting with levels of the one or more biomarkers or levels of the specific panel of biomarkers less than the reference standard would be a candidate for treatment for pancreatic cancer, treatment for pancreatitis, or with more aggressive therapy for pancreatic cancer or pancreatitis.
  • an individual presenting with levels of the one or more biomarkers or levels of the specific panel of biomarkers greater than or equal to the reference standard would be less likely to have pancreatic cancer or pancreatitis and therefore be a candidate for no treatment for pancreatic cancer, no treatment for pancreatitis, delayed treatment for pancreatic cancer, delayed treatment for pancreatitis or less aggressive treatment for pancreatic cancer or pancreatitis.
  • a patient is treated more or less aggressively than a reference therapy.
  • a reference therapy is any therapy that is the standard of care for chronic pancreatitis or pancreatic cancer.
  • the standard of care can vary temporally and geographically, and a skilled person can easily determine the appropriate standard of care by consulting the relevant medical literature.
  • treatment will be either 1) more aggressive, or 2) less aggressive than a standard therapy.
  • a more aggressive therapy than the standard therapy comprises beginning treatment earlier than in the standard therapy.
  • a more aggressive therapy than the standard therapy comprises treating on an accelerated schedule compared to the standard therapy. In some embodiments, a more aggressive therapy than the standard therapy comprises administering additional treatments not called for in the standard therapy.
  • a less aggressive therapy than the standard therapy comprises delaying treatment relative to the standard therapy. In some embodiments, a less aggressive therapy than the standard therapy comprises administering less treatment than in the standard therapy. In some embodiments, a less aggressive therapy than the standard therapy comprises administering treatment on a decelerated schedule compared to the standard therapy. In some embodiments, a less aggressive therapy than the standard therapy comprises administering no treatment.
  • Health practitioners treat chronic pancreatitis by taking actions to ameliorate the causes or symptoms of the disorder in a patient.
  • Treatment may comprise drug- based or non-drug-based therapies.
  • Drug-based therapies may include: selecting and administering one or more drugs to the patient, adjusting the dosage of a drug, adjusting the dosing schedule of a drug, and adjusting the length of the therapy with a drug.
  • Drugs are selected by practitioners based on the nature of the symptoms and the patient's response to any previous treatments.
  • the dosage of a drug can be adjusted as well by the practitioner based on the nature of the drug, the nature of the patient's symptoms, the patient's response to previous treatment, and the patient's response to the drug.
  • the dosing schedule can also be adjusted by the practitioner based on the nature of the drug, the nature of the patient's symptoms, the patient's response to previous treatment, and the patient's response to the drug.
  • the length of the therapy can be adjusted by the practitioner based on the nature of the drug, the nature of the patient's symptoms, the patient's response to previous treatment, and the patient's response to the drug. Additionally, the practitioner can select between a single drug therapy, a dual drug therapy, or a triple drug therapy. In some embodiments, a practitioner may optionally treat the patient with a combination of one or more drugs and one or more non-drug-based therapies.
  • the practitioner begins therapy based on a comparison between a reference level and the levels of one or more biomarkers or the levels of a specific panel of biomarkers in a sample from a patient.
  • the comparison between a reference level and the levels of one or more biomarkers or the levels of a specific panel of biomarkers comprises using the levels of the biomarkers in a biological sample from the patient to derive a score
  • therapy comprises the selection and administration of a drug to the patient by the practitioner.
  • therapy comprises the selection and administration of two drugs to the patient by the practitioner as part of dual therapy.
  • therapy comprises the selection and administration of three drugs to the patient by the practitioner as part of triple therapy.
  • treatment comprises administering to an individual an analgesic agent. In some embodiments, treatment comprises administering to an individual uncoated pancreatic enzymes.
  • a practitioner may also treat an individual with non-drug based therapies.
  • the non-drug based therapy comprises Endoscopic therapy aimed at decompressing an obstructed pancreatic duct.
  • the non-drug based therapy comprises pancreatic duct drainage.
  • the non-drug based therapy comprises pancreatic resection.
  • the non-drug based therapy comprises total pancreatectomy and islet autotransplantation.
  • the practitioner adjusts the therapy based on a comparison between a reference level and the levels of one or more biomarkers or the levels of a specific panel of biomarkers in a sample from a patient. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different combination of drugs. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage. In one embodiment, the practitioner adjusts the therapy by adjusting dose schedule. In one embodiment, the practitioner adjusts the therapy by adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug combination and adjusting drug dosage.
  • the practitioner adjusts the therapy by selecting and administering a different drug combination and adjusting dose schedule. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug combination and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage and dose schedule. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by adjusting dose schedule and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug, adjusting drug dosage, and adjusting dose schedule. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug, adjusting drug dosage, and adjusting length of therapy.
  • the practitioner adjusts the therapy by selecting and administering a different drug, adjusting dose schedule, and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage, adjusting dose schedule, and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug, adjusting drug dosage, adjusting dose schedule, and adjusting length of therapy.
  • treatment comprises a less aggressive therapy than a reference therapy.
  • a less aggressive therapy comprises not administering drugs and taking a "watchful waiting" approach.
  • a less aggressive therapy comprises delaying treatment.
  • a less aggressive therapy comprises selecting and administering less potent drugs.
  • a less aggressive therapy comprises decreasing dosage of drugs.
  • a less aggressive therapy comprises decreasing the frequency treatment.
  • a less aggressive therapy comprises shortening length of therapy.
  • less aggressive therapy comprises selecting and administering less potent drugs and decreasing drug dosage.
  • less aggressive therapy comprises selecting and administering less potent drugs and decelerating dose schedule.
  • less aggressive therapy comprises selecting and administering less potent drugs and shortening length of therapy.
  • less aggressive therapy comprises decreasing drug dosage and decelerating dose schedule. In one embodiment, less aggressive therapy comprises decreasing drug dosage and shortening length of therapy. In one embodiment, less aggressive therapy comprises decelerating dose schedule and shortening length of therapy. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decreasing drug dosage, and decelerating dose schedule. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decreasing drug dosage, and shortening length of therapy. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decelerating dose schedule, and shortening length of therapy. In one embodiment, less aggressive therapy comprises decreasing drug dosage, decelerating dose schedule, and shortening length of therapy. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decreasing drug dosage, decelerating dose schedule, and shortening length of therapy. In some embodiments, a less aggressive therapy comprises administering only non-drug-based therapies.
  • treatment comprises a more aggressive therapy than a reference therapy.
  • a more aggressive therapy comprises earlier administration of drugs.
  • a more aggressive therapy comprises increased dosage of drugs.
  • a more aggressive therapy comprises increased length of therapy.
  • a more aggressive therapy comprises increased frequency of the dose schedule.
  • more aggressive therapy comprises selecting and administering more potent drugs and increasing drug dosage.
  • more aggressive therapy comprises selecting and administering more potent drugs and accelerating dose schedule.
  • more aggressive therapy comprises selecting and administering more potent drugs and increasing length of therapy.
  • more aggressive therapy comprises increasing drug dosage and accelerating dose schedule.
  • more aggressive therapy comprises increasing drug dosage and increasing length of therapy.
  • more aggressive therapy comprises accelerating dose schedule and increasing length of therapy. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, increasing drug dosage, and accelerating dose schedule. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, increasing drug dosage, and increasing length of therapy. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, accelerating dose schedule, and increasing length of therapy. In one embodiment, more aggressive therapy comprises increasing drug dosage, accelerating dose schedule, and increasing length of therapy. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, increasing drug dosage, accelerating dose schedule, and increasing length of therapy. In some embodiments, a more aggressive therapy comprises administering a combination of drug- based and non-drug-based therapies.
  • Treatment may comprise drug- based or non-drug-based therapies.
  • Drug-based therapies may include: selecting and administering one or more anti-cancer, anti-tumor or chemotherapeutic drugs to the patient, adjusting the dosage of one or more of said drugs, adjusting the dosing schedule of one or more of said drugs, and adjusting the length of the therapy with an one or more of said drugs.
  • Drugs are selected by practitioners based on the nature of the symptoms and the patient's response to any previous treatments.
  • the dosage of a drug can be adjusted as well by the practitioner based on the nature of the drug, the nature of the patient's symptoms, the patient's response to previous treatment, and the patient's response to the drug.
  • the dosing schedule can also be adjusted by the practitioner based on the nature of the drug, the nature of the patient's symptoms, the patient's response to previous treatment, and the patient's response to the drug.
  • the length of the therapy can be adjusted by the practitioner based on the nature of the drug, the nature of the patient's symptoms, the patient's response to previous treatment, and the patient's response to the drug. Additionally, the practitioner can select between a single drug therapy, a dual drug therapy, or a triple drug therapy.
  • a practitioner may optionally treat the patient with a combination of one or more drugs and one or more non-drug-based therapies.
  • the practitioner begins therapy based on a comparison between a reference level and the levels of one or more biomarkers or the levels of a specific panel of biomarkers in a sample from a patient.
  • therapy comprises the selection and administration of a drug to the patient by the practitioner.
  • therapy comprises the selection and administration of two drugs to the patient by the practitioner as part of dual therapy.
  • therapy comprises the selection and
  • treatment comprises administering to an individual a chemotherapeutic agent.
  • the chemotherapeutic agent is Erlotinib Hydrochloride.
  • the chemotherapeutic agent is Fluorouracil. In some embodiments, the chemotherapeutic agent is Gemcitabine Hydrochloride. In some embodiments, the
  • chemotherapeutic agent is Mitomycin C.
  • the chemotherapeutic agent is a combination of Gemcitabine and Oxaliplatin.
  • treatment comprises administering to an individual a pain medication.
  • a practitioner may also treat an individual with non-drug-based therapies.
  • the non-drug based therapy comprises surgical resection of the cancer.
  • the non-drug based therapy comprises stent placement.
  • the non-drug based therapy comprises radiation therapy.
  • the non-drug based therapy comprises pancreatectomy.
  • the practitioner adjusts the therapy based on a comparison between a reference level and the levels of one or more biomarkers or the levels of a specific panel of biomarkers in a sample from a patient. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different combination of drugs. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage. In one embodiment, the practitioner adjusts the therapy by adjusting dose schedule. In one embodiment, the practitioner adjusts the therapy by adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug combination and adjusting drug dosage.
  • the practitioner adjusts the therapy by selecting and administering a different drug combination and adjusting dose schedule. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug combination and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage and dose schedule. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by adjusting dose schedule and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug, adjusting drug dosage, and adjusting dose schedule. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug, adjusting drug dosage, and adjusting length of therapy.
  • the practitioner adjusts the therapy by selecting and administering a different drug, adjusting dose schedule, and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by adjusting drug dosage, adjusting dose schedule, and adjusting length of therapy. In one embodiment, the practitioner adjusts the therapy by selecting and administering a different drug, adjusting drug dosage, adjusting dose schedule, and adjusting length of therapy.
  • treatment comprises a less aggressive therapy than a reference therapy.
  • a less aggressive therapy comprises not administering drugs and taking a "watchful waiting" approach.
  • a less aggressive therapy comprises delaying treatment.
  • a less aggressive therapy comprises selecting and administering less potent drugs.
  • a less aggressive therapy comprises decreasing dosage of drugs.
  • a less aggressive therapy comprises decreasing the frequency treatment.
  • a less aggressive therapy comprises shortening length of therapy.
  • less aggressive therapy comprises selecting and administering less potent drugs and decreasing drug dosage.
  • less aggressive therapy comprises selecting and administering less potent drugs and decelerating dose schedule.
  • less aggressive therapy comprises selecting and administering less potent drugs and shortening length of therapy.
  • less aggressive therapy comprises decreasing drug dosage and decelerating dose schedule. In one embodiment, less aggressive therapy comprises decreasing drug dosage and shortening length of therapy. In one embodiment, less aggressive therapy comprises decelerating dose schedule and shortening length of therapy. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decreasing drug dosage, and decelerating dose schedule. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decreasing drug dosage, and shortening length of therapy. In one embodiment, less aggressive therapy comprises selecting and administering less potent drugs, decelerating dose schedule, and shortening length of therapy. In one embodiment, less aggressive therapy comprises decreasing drug dosage, decelerating dose schedule, and shortening length of therapy. In one embodiment, less aggressive therapy comprises decreasing drug dosage, decelerating dose schedule, and shortening length of therapy.
  • less aggressive therapy comprises selecting and administering less potent drugs, decreasing drug dosage, decelerating dose schedule, and shortening length of therapy.
  • a less aggressive therapy comprises administering only non-drug-based therapies.
  • the practitioner reflexes to further tests such as imaging.
  • treatment comprises a more aggressive therapy than a reference therapy.
  • a more aggressive therapy comprises earlier administration of drugs.
  • a more aggressive therapy comprises increased dosage of drugs.
  • a more aggressive therapy comprises increased length of therapy.
  • a more aggressive therapy comprises increased frequency of the dose schedule.
  • more aggressive therapy comprises selecting and administering more potent drugs and increasing drug dosage.
  • more aggressive therapy comprises selecting and administering more potent drugs and accelerating dose schedule.
  • more aggressive therapy comprises selecting and administering more potent drugs and increasing length of therapy.
  • more aggressive therapy comprises increasing drug dosage and accelerating dose schedule.
  • more aggressive therapy comprises increasing drug dosage and increasing length of therapy.
  • more aggressive therapy comprises accelerating dose schedule and increasing length of therapy. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, increasing drug dosage, and accelerating dose schedule. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, increasing drug dosage, and increasing length of therapy. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, accelerating dose schedule, and increasing length of therapy. In one embodiment, more aggressive therapy comprises increasing drug dosage, accelerating dose schedule, and increasing length of therapy. In one embodiment, more aggressive therapy comprises selecting and administering more potent drugs, increasing drug dosage, accelerating dose schedule, and increasing length of therapy. In some embodiments, a more aggressive therapy comprises administering a combination of drug- based and non-drug-based therapies.
  • the present disclosure also includes methods of determining the probability of early-stage pancreatic cancer, wherein the methods comprise determining from a biological sample of a patient the level of each biomarker of a panel of biomarkers for pancreatic cancer, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of each biomarker to threshold levels for each biomarker.
  • the methods may further comprise determining the number of patient biomarkers that have either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods may further comprise calculating the probability of early-stage pancreatic cancer based on the above-determined number.
  • the methods further comprise determining the number of family members of the patient diagnosed with pancreatic cancer and determining the degree of relationship to the patient of any such family member.
  • calculating the probability of early-stage pancreatic cancer may be further based on the number of family members of the patient diagnosed with pancreatic cancer and the degree of relationship to the patient of any such family member.
  • the methods further comprise determining the magnitude of the difference in level for each biomarker of the patient that is either above a threshold level for that particular positive biomarker or below a threshold level for that particular negative biomarker. In such embodiments, calculating the probability of early-stage pancreatic cancer may be further based on such magnitude of the difference in level. [0043] In some embodiments, calculating the probability of early-stage pancreatic cancer is also based on the weighted significance of each patient biomarker that has either a level above the threshold level for each particular positive biomarker or a level below the threshold level for each particular negative biomarker.
  • the methods further comprise determining the presence or absence of a mutation in a BRCA2, PALB2, p l 6, STK1 1 , MLH 1 , MSH2, MSH6, PMS2, or EPCAM gene of the patient, or determining whether the patient has hereditary non-polyposis colorectal cancer.
  • calculating the probability of early-stage pancreatic cancer may be further based on the presence or absence of a mutation in a BRCA2, PALB2, p l 6, STK1 1 , MLH 1 , MSH2, MSH6, PMS2, or EPCAM gene or whether the patient has hereditary non-polyposis colorectal cancer.
  • methods of determining the probability of early-stage pancreatic cancer comprise determining the number of family members of the patient diagnosed with pancreatic cancer and determining the degree of relationship to the patient of any such family member; determining the presence or absence of a mutation in a BRCA2, PALB2, p l 6, STK1 1 , MLH 1 , MSH2, MSH6, PMS2, or EPCAM gene of the patient, or determining whether the patient has hereditary non-polyposis colorectal cancer; determining from a biological sample of the patient the level of each biomarker of a panel of biomarkers for pancreatic cancer, wherein the panel comprises positive biomarkers, negative biomarkers, or both; comparing the level of each biomarker to threshold levels for each biomarker; determining the number of patient biomarkers that have either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker; determining the magnitude of the difference in level for each biomark
  • an algorithm is used to calculate the probability of pancreatic cancer.
  • a score is calculated from a statistical model as described herein to indicate the probability of pancreatic cancer.
  • the algorithm or score incorporates secondary indications, such as the patient' s family and personal medical history.
  • the present disclosure also includes methods of screening for further diagnosis of pancreatic cancer, wherein the methods comprise determining from a biological sample of a patient a level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of each biomarker to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods may further comprise conducting endoscopic ultrasonography or magnetic resonance cholangiopancreatography if such a biomarker is present. In some of such embodiments, the methods further comprise conducting endoscopic ultrasonography or magnetic resonance cholangiopancreatography if the patient has at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 such biomarkers present.
  • the present disclosure also includes methods of screening a biological sample, wherein the methods comprise obtaining a biological sample and determining a level in the biological sample of a panel of biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of each biomarker to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods comprise determining a level in the biological sample of each biomarker of the panel.
  • the method may be performed on a sample from an individual who is at higher than population risk for pancratic cancer.
  • the method comprises identifying an individual for screening. Identifying an individual for screening may involve identifying an individual with any of the following indications: history of chronic pancreatitis, episodes of abdominal pain, personal history of heavy alcohol use, hereditary disorder of the pancreas, hereditary
  • pancreatitis cystic fibrosis, hypercalcemia, hyperlipidemia, hypertriglyceridemia, and/or autoimmune disorder(s) that increase the likelihood of developing pancreatitis.
  • the patient additionally has risk factors for developing pancreatic cancer including any one or more of: a first degree relative with pancreatic cancer, a diagnosis or symptoms of Lynch syndrome, a diagnosis of new-onset diabetes, a diagnosis of diabetes, and/or a diagnosis or symptoms of Peutz-Jeghers syndrome.
  • a patient has at least one mutation in any one or more of the following genes: BRCA2, PALB2, pl6, STKl 1, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
  • the present disclosure also includes methods of screening for further diagnosis of chronic pancreatitis, wherein the methods comprise determining from a biological sample of a patient a level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of each biomarker to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods may further comprise conducting endoscopic ultrasonography or magnetic resonance cholangiopancreatography if such a biomarker is present. In some of such embodiments, the methods further comprise conducting endoscopic ultrasonography or magnetic resonance cholangiopancreatography if the patient has at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 such biomarkers present.
  • the present disclosure also includes methods of screening a biological sample, wherein the methods comprise obtaining a biological sample and determining a level in the biological sample of a panel of biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both.
  • the methods may further comprise comparing the level of each biomarker to threshold levels for each biomarker.
  • the methods may further comprise determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods comprise determining a level in the biological sample of each biomarker of the panel.
  • the method may be performed on a sample from an individual who is at higher than population risk for chronic pancratitis.
  • the method comprises identifying an individual for screening. Identifying an individual for screening may involve identifying an individual with any of the following indications: history of chronic pancreatitis, episodes of abdominal pain, personal history of heavy alcohol use, hereditary disorder of the pancreas, hereditary
  • pancreatitis cystic fibrosis, hypercalcemia, hyperlipidemia, hypertriglyceridemia, and/or autoimmune disorder(s) that increase the likelihood of developing pancreatitis.
  • the patient additionally has risk factors for developing pancreatic cancer including any one or more of: a first degree relative with pancreatic cancer, a diagnosis or symptoms of Lynch syndrome, a diagnosis of new-onset diabetes, a diagnosis of diabetes, and/or a diagnosis or symptoms of Peutz-Jeghers syndrome.
  • a patient has at least one mutation in any one or more of the following genes: BRCA2, PALB2, pl6, STK1 1, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
  • results of any analyses according to the invention will often be communicated to physicians, patients, or other interested parties in a transmittable form that can be communicated or transmitted to any of the above parties.
  • a transmittable form can vary and can be tangible or intangible.
  • the results can be embodied in descriptive statements, diagrams, photographs, charts, images or any other visual forms. For example, graphs of levels for various biomarkers can be used in explaining the results. In some embodiments, a graph of the probability of cancer in the individual related to the reference population is provided. Diagrams showing such information for additional target biomarkers(s) are also useful in indicating some testing results.
  • statements and visual forms can be recorded on a tangible medium such as papers, computer readable media such as floppy disks, compact disks, etc., or on an intangible medium, e.g., an electronic medium in the form of email or website on internet or intranet.
  • results can also be recorded in a sound form and transmitted through any suitable medium, e.g., analog or digital cable lines, fiber optic cables, etc., via telephone, facsimile, wireless mobile phone, internet phone and the like.
  • the information and data on a test result can be produced anywhere in the world and transmitted to a different location.
  • the information and data on a test result may be generated, cast in a transmittable form as described above, and then imported into the United States.
  • the present invention also encompasses methods and systems for producing a transmittable form of biomarker information for at least one patient sample.
  • the method comprises the steps of (1) measuring the levels of biomarkers in a sample according to methods of the present invention; and (2) embodying the result of the levels of biomarkers in a transmittable form.
  • the transmittable form is a product of such a method.
  • the computer-based analysis function can be implemented in any suitable language and/or browsers. For example, it may be implemented with C language and preferably using object-oriented high-level programming languages such as Visual Basic, SmallTalk, C++, and the like.
  • the application can be written to suit environments such as the Microsoft
  • WindowsTM environment including WindowsTM 98, WindowsTM 2000, WindowsTM NT, and the like.
  • the application can also be written for the MacintoshTM, SUNTM, UNIX or LINUX environment.
  • the functional steps can also be implemented using a universal or platform- independent programming language. Examples of such multi-platform programming languages include, but are not limited to, hypertext markup language (HTML), JAVATM, JavaScriptTM, Flash programming language, common gateway interface/structured query language (CGI/SQL), practical extraction report language (PERL), AppleScriptTM and other system script languages, programming language/structured query language (PL/SQL), and the like.
  • JavaTM- or JavaScriptTM-enabled browsers such as HotJavaTM, MicrosoftTM ExplorerTM, or Netscape can be used.
  • active content web pages may include Java applets or ActiveXTM controls or other active content technologies.
  • the analysis function can also be embodied in computer program products and used in the systems described above or other computer- or internet-based systems.
  • another aspect of the present invention relates to a computer program product comprising a computer-usable medium having computer-readable program codes or instructions embodied thereon for enabling a processor to carry out gene or protein status analysis.
  • These computer program instructions may be loaded onto a computer or other programmable apparatus to produce a machine, such that the instructions which execute on the computer or other programmable apparatus create means for implementing the functions or steps described above.
  • These computer program instructions may also be stored in a computer-readable memory or medium that can direct a computer or other programmable apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory or medium produce an article of manufacture including instruction means which implement the analysis.
  • the computer program instructions may also be loaded onto a computer or other programmable apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions or steps described above.
  • the present disclosure also includes computer-assisted methods of determining the probability of a patient having early-stage pancreatic cancer or chronic pancreatitis, or chronic pancreatitis with pancreatic cancer of some stage wherein the methods comprise providing biomarker information from a biomarker information database module on a data processing device, wherein the biomarker information comprises threshold level information for each biomarker of a panel of biomarkers, wherein the panel of biomarkers comprises positive biomarkers, negative biomarkers, or both, wherein a level above a threshold level for positive biomarkers is indicative of the presence of pancreatic cancer or chronic pancreatitis or chronic pancreatitis with pancreatic cancer of some stage in a patient and a level below a threshold level for negative biomarkers is indicative of the presence of pancreatic cancer or chronic pancreatitis or chronic pancreatitis with pancreatic cancer of some stage in a patient.
  • the methods may further comprise providing patient information from a patient information database module on a data processing device, wherein the patient information comprises biomarker level information for the patient.
  • the methods may further comprise comparing with a comparison module on a data processing device biomarker information and patient information.
  • the methods may further comprise determining with an evaluation module on a data processing device operably connected to the comparison module a number of patient biomarkers with either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the methods may further comprise determining with a calculation module on a data processing device operably connected to the evaluation module a probability of early-stage pancreatic cancer or chronic pancreatitis or chronic pancreatitis with pancreatic cancer of some stage based on the number of patient biomarkers with either a level above the threshold level for each particular positive biomarker or a level below the threshold level for each particular negative biomarker.
  • the methods further comprise providing to the calculation module family history information from a family history database module on a data processing device, the family history information comprising the number of family members of the patient diagnosed with pancreatic cancer, and wherein determining a probability of early- stage pancreatic cancer is further based on the number of family members of the patient diagnosed with pancreatic cancer.
  • the family history information may comprise the degree of relationship to the patient of each family member diagnosed with pancreatic cancer.
  • the family history database may comprise a patient file history database.
  • the patient information database comprises a patient file history database.
  • the methods further comprise displaying a graphical presentation of the patient's probability of early-stage pancreatic cancer or chronic pancreatitis with a display operably connected to the calculation module.
  • the methods further comprise determining additional suggested diagnostic procedures based on the patient's probability of early-stage pancreatic cancer or chronic pancreatitis with a diagnostic module operably connected to the calculation module.
  • Figure 1 illustrates a system for performing computer-assisted methods of determining the probability of a patient having early-stage pancreatic cancer or chronic pancreatitispancreatic cancer.
  • System 100 comprises a data processing device 10 comprising a biomarker information database module 1 1.
  • the biomarker information database module 11 comprises biomarker information comprising threshold level information for each biomarker of a panel of biomarkers, wherein the panel of biomarkers comprises positive biomarkers, negative biomarkers, or both, wherein a level above a threshold level for each particular positive biomarker is indicative of the presence of pancreatic cancer or chronic pancreatitis with pancreatic cancer of some stage in a patient and a level below a threshold level for each particular negative biomarker is indicative of the presence of pancreatic cancer or chronic pancreatitis or chronic pancreatitis with pancreatic cancer of some stage in a patient.
  • the system 100 further comprises a data processing device 20 comprising a patient information database module 21.
  • the patient information database module 21 comprises patient information comprising biomarker level information for a patient.
  • the system 100 further comprises a data processing device 30 comprising a comparison module 31.
  • the comparison module 31 may be in communication with the biomarker information database module 11 and the patient information database module 21.
  • the comparison module 31 may be configured to compare biomarker information and patient information.
  • the data processing device 30 may further comprise an evaluation module 32 in communication with the comparison module 31.
  • the evaluation module 32 may be configured to determine a number of patient biomarkers with either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • the data processing device 30 may further comprise a calculation module 33 in communication with the evaluation module 32.
  • the calculation module 33 may be configured to determine a probability of early-stage pancreatic cancer or chronic pancreatitis based on the number of patient biomarkers with either a level above the threshold level for each particular positive biomarker or a level below the threshold level for each particular negative biomarker.
  • the data processing device 30 may further comprise a diagnostic module 34 in communication with the calculation module 33.
  • the diagnostic module 34 may be configured to determine additional suggested diagnostic procedures based on a patient's probability of early-stage pancreatic cancer or chronic pancreatitis.
  • the system 100 further comprises a data processing device 40 comprising a family history database module 41.
  • the family history database module 41 may comprise family history information comprising the number of family members of a patient diagnosed with pancreatic cancer or chronic pancreatitis. The family history information may also comprise the degree of relationship to a patient of each family member diagnosed with pancreatic cancer or chronic pancreatitis.
  • the family history database module 41 may be in communication with the calculation module 33.
  • the calculation module 33 may be configured to utilize family history information in determining the probability of early-stage pancreatic cancer or chronic pancreatitis of a patient.
  • the system 100 further comprises a display 50 in communication with the calculation module 33 and configured to display a graphical representation of a patient's probability of early-stage pancreatic cancer or chronic pancreatitis or both.
  • the various features of the methods may be embodied in machine-executable instructions executed by a general-purpose or special-purpose computer (or other electronic device).
  • the features may be performed by hardware components that include specific logic for performing the steps or by a combination of hardware, software, and/or firmware.
  • modules within a system.
  • a system may be implemented in software, firmware, hardware, and/or physical infrastructure.
  • a module may be identified (named) based on a function it performs.
  • a module that is configured to calculate something may comprise specific hardware, software, or firmware and be properly referred to as a "calculation module.”
  • Embodiments may also be provided as a computer program product including a non-transitory machine-readable medium having stored thereon instructions that may be used to program, or be executed on, a computer (or other electronic device) to perform processes described herein.
  • the machine-readable medium may include, but is not limited to, hard drives, floppy diskettes, optical disks, CD-ROMs, DVD-ROMs, ROMs, RAMs, EPROMs, EEPROMs, magnetic or optical cards, solid-state memory devices, or other types of
  • a computer program product may be run, executed, downloaded, and/or otherwise used locally or remotely via a network.
  • references to "a data processing device” may refer to the same device or one or more different devices. For example, certain steps of the computer-assisted methods may be performed on a device controlled by a diagnostic service provider and other steps may be performed on a device controlled by a medical practitioner.
  • the data processing devices 10, 20, 30 and 40 may be a single device or, for example, the data processing device 30 may be multiple data processing devices.
  • the computer-implemented method may be configured to identify a patient as having or not having pancreatic cancer. For example, the computer-implemented method may be configured to inform a physician that a particular patient has pancreatic cancer or a probability of having pancreatic cancer. Alternatively or additionally, the computer-implemented method may be configured to actually suggest a particular course of treatment based on the answers to/results for various queries, or refer the patient for further testing.
  • the present disclosure also includes a kit for detecting the presence of early-stage pancreatic cancer or chronic pancreatitis in a patient, the kit comprising reagents useful, sufficient, or necessary for determining the level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • kits for practicing the diagnosis of the present invention.
  • the kit may include a carrier for the various components of the kit.
  • the carrier can be a container or support, in the form of, e.g., bag, box, tube, rack, and is optionally compartmentalized.
  • the carrier may define an enclosed confinement for safety purposes during shipment and storage.
  • the kit may include antibodies directed to proteins of a panel of biomarkers in any of Panels A-L.
  • the kit may include oligonucleotides directed to mRNA or cDNA of a panel of biomarkers in any of Panels A-L.
  • the kit comprises reagents (e.g., probes, primers, and or antibodies) for determining the levels of a panel of biomarkers, where said panel comprises at least 5% 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 90%, 95%, 99%, or 100% biomarkers from Panels A-L.
  • the kit consists of reagents (e.g., probes, primers, and or antibodies) for determining the expression level of no more than 2500 genes, wherein at least 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, or more of these biomarkers are from Panels A-L.
  • the kit may contain capture antibodies (in some embodiments monoclonal), detection antibodies (in some embodiments monoclonal), antigen control reagents, fluorophores/reporter molecules, buffer, blockers, stabilizers, etc.
  • the panel of biomarkers may comprise any one of the panels described herein.
  • the panel is panel A.
  • the panel is panels B.
  • the panel is panel C.
  • the panel is panel D.
  • the panel is panel E.
  • the panel is panel F.
  • the panel is panel G.
  • the panel is panel H.
  • the panel is panel I.
  • the panel is panel J.
  • the panel is panel K.
  • the panel is panel L.
  • the panel is any three biomarkers from any one of panels A, B, C, D, E, F, G, H, I, J, K or L. In some embodiments, the panel is any four biomarkers from any one of panels A, B, C, D, E, F, G, H, I, J, K or L. In some embodiments, the panel is any five biomarkers from any one of panels A, B, C, D, E, F, G, H, I, J, K or L.
  • the panel is one of the 3 biomarker panels disclosed in Megatable 3 , respectively. In one group of individual embodiments, the panel is one of the 3 biomarker panels disclosed in Megatable 6, respectively. In one group of individual embodiments, the panel is one of the 3 biomarker panels disclosed in Megatable 9, respectively. In one group of individual embodiments, the panel is one of the 3 biomarker panels disclosed in Megatable 12, respectively.
  • the panel is one of the 4 biomarker panels disclosed in Megatable 4, respectively. In one group of individual embodiments, the panel is one of the 4 biomarker panels disclosed in Megatable 7, respectively. In one group of individual embodiments, the panel is one of the 4 biomarker panels disclosed in Megatable 10, respectively. In one group of individual embodiments, the panel is one of the 4 biomarker panels disclosed in Megatable 13 , respectively.
  • the panel is one of the 5 biomarker panels disclosed in Megatable 5, respectively. In one group of individual embodiments, the panel is one of the 5 biomarker panels disclosed in Megatable 8, respectively. In one group of individual embodiments, the panel is one of the 5 biomarker panels disclosed in Megatable 1 1 , respectively. In one group of individual embodiments, the panel is one of the 5 biomarker panels disclosed in Megatable 14, respectively.
  • the panel is comprised of the top 2, 3, 4, 5,
  • the biomarkers are ranked by p-value, AUC, q-value, or some combination of these to determine the top biomarkers.
  • the methodology used to generate the multivariate model comprises random forest, boosting or lasso.
  • the panel comprises top 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 of the biomarkers disclosed in any of the columns of Tables 3 - 10 or 14-24.
  • the panel comprises any 2, 3, 4, 5, 6, 7, 8, 9,
  • each embodiment includes at least 5 biomarkers, at least 6 biomarkers, at least 7 biomarkers, at least 8 biomarkers, at least 9 biomarkers, at least 10 biomarkers, at least 1 1 biomarkers, at least 12 biomarkers, at least 13 biomarkers, at least 14 biomarkers, at least 15 biomarkers, at least 20 biomarkers, at least 25 biomarkers, at least 30 biomarkers, at least 35 biomarkers, at least 40 biomarkers, at least 45 biomarkers, or at least 50 biomarkers of the panel, depending on the number of biomarkers in the panel, up to and including the total number of biomarkers in the panel.
  • the biological sample may be a sample from any bodily fluid, tissue, or substance.
  • the biological sample may comprise or originate from a blood sample, a urine sample, a fecal sample, a saliva sample, or a pancreatic tissue sample.
  • the biological sample is a blood plasma sample.
  • the level may be any direct or indirect measure of the quantity of the biomarker.
  • the level may comprise the concentration of a protein or other gene product corresponding to the biomarker in a biological sample.
  • the level may comprise the concentration of a transcript that encodes for a protein corresponding to the biomarker.
  • the level may comprise the expression level in a tissue sample of nucleic acids corresponding to the biomarker.
  • positive biomarker refers to a biomarker for which a level above a threshold level for that biomarker is indicative of the presence of pancreatic cancer or chronic pancreatitis in a patient.
  • negative biomarker refers to a biomarker for which a level below a threshold level for that biomarker is indicative of the presence of pancreatic cancer or chronic pancreatitis in a patient.
  • threshold level refers to the positive or negative value at which a biomarker becomes indicative of the presence of pancreatic cancer in a patient. Methods of determining biomarker threshold levels are known in the art.
  • the threshold level may be the upper and/or lower boundary of the normal distribution of the level a particular biomarker in a particular population, such as a generic population or a specific population.
  • a specific population is a group of individuals that share a common mutation or heritage.
  • the threshold level may be specific to a particular individual. In that case, a relative increase or decrease in the level of a particular biomarker over time may be indicative of the presence of pancreatic cancer in the individual.
  • pancreatic cancer means malignant cells arising from tissue in the pancreas.
  • pancreatic cancer is adenocarcinoma.
  • pancreatic cancer is pancreatic ductal adenocarcinoma.
  • Protein A is defined as: 6Ckine, Adiponectin, Agouti-Related Protein
  • AgRP Aldose Reductase, Alpha-l-acid glycoprotein 1 ( AGP-1), Alpha- 1-Antichymotrypsin (AACT), Alpha- 1 -Antitrypsin (AAT), Alpha- 1 -Microglobulin (A 1 Micro), Alpha-2- Macroglobulin (A2Macro), AlphA-Letoprotein (AFP), Amphiregulin (AR), Angiogenin, Angiopoietin-1 (ANG-1), Angiopoietin-2 (ANG-2), Angiopoietin-related protein 3 (ANGPTL3), Angiotensin-Converting Enzyme (ACE), Angiotensinogen, Antileukoproteinase (ALP), Antithrombin-III (AT-III), Apolipoprotein(a) (Lp(a)), Apolipoprotein A-I (Apo A-I),
  • Apolipoprotein A-II (Apo A-II), Apolipoprotein A-IV (Apo A-IV), Apolipoprotein B (Apo B), Apolipoprotein C-I (Apo C-I), Apolipoprotein C-III (Apo C-III), Apolipoprotein D (Apo D), Apolipoprotein E (Apo E), Apolipoprotein H (Apo H), AXL Receptor Tyrosine Kinase (AXL), B cell-activating factor (BAFF), B Lymphocyte Chemoattractant (BLC), Beta-2 -Microglobulin (B2M), Beta-microseminoprotein (PSP94), Betacellulin (BTC), Brain-Derived Neurotrophic Factor (BDNF), C-Peptide, C-Reactive Protein (CRP), Cadherin-1 (E-Cad), Cadherin-13 (T- cad), Calbindin, Cancer Antigen 125 (CA
  • Complement component Clq receptor ClqRl
  • Complement Factor H - Related Protein 1 ClqRl
  • CCFHR1 Complement Factor H - Related Protein 1
  • Cortisol Cortisol
  • Creatine Kinase-MB CK-MB
  • Cystatin-A Cystatin-B
  • Cystatin- C Decorin
  • DKK-1 Dickkopf-related protein 1
  • DPPIV Dipeptidyl peptidase IV
  • E-Selectin EN-RAGE, Endoglin, Endostatin, Eotaxin-1, Eotaxin-2, Eotaxin-3
  • Epidermal Growth Factor EGF
  • Epidermal Growth Factor Receptor EGFR
  • Epiregulin EPR
  • Epithelial cell adhesion molecule EpCam
  • Epithelial-Derived Neutrophil-Activating Protein 78 Ezrin
  • Factor VII Fas Ligand
  • FASLG Receptor FAS
  • hCG Gonadotropin beta
  • HER-2 Human Epidermal Growth Factor Receptor 2
  • Immunoglobulin A (IgA), Immunoglobulin E (IgE), Immunoglobulin M (IgM), Insulin, Insulin- like Growth Factor-Binding Protein 1 (IGFBP-1), Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Insulin-like Growth Factor-Binding Protein 3 (IGFBP-3), Insulin-like Growth Factor Binding Protein 4 (IGFBP4), Insulin-like Growth Factor Binding Protein 5 (IGFBP5), Insulin- like Growth Factor Binding Protein 6 (IGFBP6), Intercellular Adhesion Molecule 1 (ICAM-1), Interferon alpha (IFN-alpha), Interferon gamma (IFN-gamma), Interferon gamma Induced Protein 10 (IP- 10), Interferon- inducible T-cell alpha chemoattractant (ITAC), Interleukin-1 alpha (IL-1 alpha), Interleukin-1 beta (IL-1 beta
  • Interleukin-2 (IL-2), Interleukin-2 receptor alpha (IL-2 receptor alpha), Interleukin-3 (IL-3), Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-6 (IL-6), Interleukin-6 receptor (IL-6r), Interleukin-6 receptor subunit beta (IL-6R beta), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Interleukin-12 Subunit p40 (IL-12p40), Interleukin-12 Subunit p70 (IL- 12p70), Interleukin-13 (IL-13), Interleukin-15 (IL-15), Interleukin-16 (IL-16), Interleukin-17 (IL-17), Interleukin-18 (IL-18), Interleukin-18-binding protein (IL-18bp), Interleukin-22 (IL-22), Interleukin-23 (IL-23), Interleukin-31 (IL-31), Kallikrein 5, Kidney Injury Molecule-1 (KIM-1
  • Macrophage Migration Inhibitory Factor MIF
  • Macrophage- Stimulating Protein MSP
  • Malondialdehy de-Modified Low-Density Lipoprotein MDA-LDL
  • Maspin MEF
  • Mast/stem cell growth factor receptor SCFR
  • Matrix Metalloproteinase- 1 MMP-1
  • Matrix Metalloproteinase- 1 MMP-1
  • MMP-3 Matrix Metalloproteinase-3
  • MMP-7 Matrix Metalloproteinase-7
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-10 Matrix Metalloproteinase- 10
  • MSLN Mesothelin
  • MSLN MHC class I chain-related protein A
  • MICA MHC class I chain-related protein A
  • MICA MHC class I chain-related protein A
  • MIG Monokine Induced by Gamma Interferon
  • MIG Myeloid Progenitor Inhibitory Factor 1
  • MPIF-1 Myeloid Progenitor Inhibitory Factor 1
  • MPO Myeloperoxid
  • PCAM-1 Platelet-Derived Growth Factor BB
  • PDGF-BB Platelet-Derived Growth Factor BB
  • Progesterone Progranulin, Proinsulin, Intact, Proinsulin, Total, Prolactin (PRL), Prostasin, Prostate-Specific Antigen, Free (PSA-L), Prostate Specific Antigen, total (tPSA), Protein S100-A4 (S100-A4), Pulmonary and Activation-Regulated Chemokine (PARC), Pulmonary surfactant-associated protein D (SP-D), Receptor for advanced glycosylation end products (RAGE), Receptor tyrosine-protein kinase erbB-3 (ErbB3), Resistin, Retinol-binding protein 4 (RBP-4), S 100 calcium-binding protein B (S100-B), Selenoprotein P , Serotransferrin (Transferrin), Serum Amyloid A Protein (SAA), Serum Amyloid P
  • Thyroglobulin TG
  • Thyroid-Stimulating Hormone Thyroid-Stimulating Hormone
  • TG Thyroxine-Binding Globulin
  • Tissue Inhibitor of Metalloproteinases 1 Thyroid-Stimulating Hormone
  • Tissue Inhibitor of Metalloproteinases 2 Tissue type Plasminogen activator (tPA), TNF -Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL-R3)
  • TGF-alpha TGF-alpha
  • TGF-beta-3 TGF-beta-3
  • TTR Trefoil Factor 3
  • TNF-alpha Tumor Necrosis Factor alpha
  • TNF-beta Tumor necrosis factor ligand superfamily member 12 (Tweak), Tumor necrosis factor ligand superfamily member 13
  • Tumor Necrosis Factor Receptor I Tumor Necrosis Factor Receptor I
  • Tumor necrosis factor receptor 2 Tumor necrosis factor receptor 2
  • Tyrosine kinase with Ig and EGF homology domains 1 Tie-1
  • Tyrosine kinase with Ig and EGF homology domains 2 TIE-2
  • Urokinase-type Plasminogen Activator uPA
  • Urokinase-type plasminogen activator receptor uPAR
  • Vascular Cell Adhesion Molecule- 1 VCAM-1
  • Vascular Endothelial Growth Factor VEGF
  • Vascular endothelial growth factor B Vascular endothelial growth factor B
  • VEGF-C Vascular Endothelial Growth Factor C
  • VEGF-D Vascular endothelial growth factor D
  • VEGF-D Vascular Endothelial Growth Factor Receptor 1
  • VGFFR-1 Vascular Endothelial
  • Protein B is defined as : 6Ckine, Alpha- 1 -Antichymotrypsin (AACT),
  • Alpha- 1 -Antitrypsin (AAT), AlphA-Letoprotein (AFP), Apolipoprotein A-I (Apo A-I), Cancer Antigen 19-9 (CA-19-9), Cancer Antigen 72-4 (CA 72-4), Cathepsin D, E-Selectin, Ferritin (FRTN), Interleukin-8 (IL-8), Leucine-rich alpha-2-glycoprotein (LRG1), Mast/stem cell growth factor receptor (SCFR), Matrix Metalloproteinase-7 (MMP-7), Osteopontin, Pentraxin-3 (PTX3), Pulmonary surfactant-associated protein D (SP-D), Selenoprotein P , Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), and Tumor necrosis factor ligand superfamily member 12 (Tweak).
  • AAT Alpha- 1 -Antitrypsin
  • AFP Alpha- 1 -Letoprotein
  • AFP Alpha- 1 -Letoprotein
  • Protein C is defined as : 6Ckine, Alpha- 1 -Antichymotrypsin (AACT),
  • Alpha-2-Macroglobulin A2Macro
  • Antithrombin-III Apolipoprotein A-I
  • B cell-activating factor BAFF
  • Cancer Antigen 19-9 CA-19-9
  • Chromogranin-A CgA
  • Creatine Kinase-MB CK-MB
  • E-Selectin Factor VII
  • Interleukin-1 alpha IL-1 alpha
  • Interleukin-8 IL-8
  • MDC Macrophage-Derived Chemokine
  • SCFR Matrix Metalloproteinase-3
  • Osteopontin Pepsinogen I
  • Proinsulin Total
  • Pulmonary surfactant-associated protein D SP-D
  • Receptor for advanced glycosylation end products RAGE
  • Stem Cell Factor SCF
  • Vascular Endothelial Growth Factor Receptor 2 VAGFR-2
  • Panel D is defined as: Alpha- 1 -acid glycoprotein 1 ( AGP-1), Alpha- 1-
  • AACT Antichymotrypsin
  • AAT Alpha- 1 -Antitrypsin
  • AAT Apolipoprotein(a)
  • Lp(a) Apolipoprotein(a)
  • CA-19-9 Cancer Antigen 19-9
  • GDF-15 Growth/differentiation factor 15
  • IL-8 Interleukin-8
  • LRG1 Leucine-rich alpha-2- glycoprotein
  • MMP-7 Matrix Metalloproteinase-7
  • Neuropilin- 1 Pentraxin-3
  • PYY Peptide YY
  • Tissue Inhibitor of Metalloproteinases 1 Tissue Inhibitor of Metalloproteinases 1
  • TNFR2 Tumor necrosis factor receptor 2
  • Protein E is defined as: Alpha- 1 -Antitrypsin (AAT), Apolipoprotein B
  • Apo B Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), CD 40 antigen (CD40), EN-RAGE, Growth/differentiation factor 15 (GDF-15), Hemopexin, Hepsin, Immunoglobulin A (IgA), Insulin-like Growth Factor Binding Protein 4 (IGFBP4), Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Interferon alpha (IFN-alpha), Interleukin- 13 (IL- 13), Interleukin-2 receptor alpha (IL-2 receptor alpha), Kidney Injury Molecule- 1 (KIM-1), Matrix Metalloproteinase-7 (MMP-7), Pancreatic secretory trypsin inhibitor (TATI), Pepsinogen I (PGI), Proinsulin, Total, Prostate-Specific Antigen, Free (PSA-L), Tissue Inhibitor of
  • TMP-1 Trefoil Factor 3
  • APRIL Tumor necrosis factor ligand superfamily member 13
  • Protein F is defined as: Amphiregulin (AR), Angiogenin, Angiopoietin-2
  • ANG-2 Angiotensin-Converting Enzyme (ACE), Angiotensinogen, Apolipoprotein(a) (Lp(a)), Apolipoprotein A-I (Apo A-I), Apolipoprotein A-II (Apo A-II), Apolipoprotein A-IV (Apo A- IV), Apolipoprotein B (Apo B), Apolipoprotein C-I (Apo C-I), Apolipoprotein C-III (Apo C-III), Apolipoprotein D (Apo D), Apolipoprotein E (Apo E), Apolipoprotein H (Apo H), AXL
  • AXL Receptor Tyrosine Kinase
  • BAFF B cell-activating factor
  • Chemoattractant BLC
  • Beta-2-Microglobulin B2M
  • Betacellulin BTC
  • Angiopoietin- 1 ANG-1
  • Antileukoproteinase ALP
  • Beta-microseminoprotein PSP94
  • Cadherin-1 E-Cad
  • Cadherin-13 T-cad
  • Carbonic anhydrase 9 CA-9
  • Carcinoembryonic antigen-related cell adhesion molecule 1 CEACAM1
  • CEACAM6 Carcinoembryonic antigen-related cell adhesion molecule 6
  • Cartilage Oligomeric Matrix Protein COMP
  • Cathepsin B pro
  • ClqRl Complement component Clq receptor
  • Cystatin-A Cystatin-B
  • Decorin Dipeptidyl peptidase IV
  • IL-18bp Interleukin- 18 -binding protein
  • IL-18bp Lactoferrin
  • LTF Lipocalin-1
  • Immunoglobulin A (IgA), Immunoglobulin E (IgE), Immunoglobulin M (IgM), Insulin, Insulin- like Growth Factor-Binding Protein 1 (IGFBP-1), Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Insulin-like Growth Factor-Binding Protein 3 (IGFBP-3), Insulin-like Growth Factor Binding Protein 4 (IGFBP4), Insulin-like Growth Factor Binding Protein 5 (IGFBP5), Insulin- like Growth Factor Binding Protein 6 (IGFBP6), Intercellular Adhesion Molecule 1 (ICAM-1), Interferon gamma (IFN-gamma), Interferon gamma Induced Protein 10 (IP- 10), Interferon- inducible T-cell alpha chemoattractant (IT AC), Interleukin- 1 alpha (IL-1 alpha), Interleukin- 1 beta (IL-1 beta), Interleukin-1 receptor antagonist (IL
  • Lactoylglutathione lyase LGL
  • LAP TGF-bl Latency-Associated Peptide of Transforming Growth Factor beta 1
  • LAP-1 Lectin-Like Oxidized LDL Receptor 1
  • Leptin Luteinizing Hormone
  • M-CSF Macrophage Colony-Stimulating Factor 1
  • MDC Macrophage-Derived Chemokine
  • MIP-1 alpha Macrophage Inflammatory Protein- 1 alpha
  • MIP- 1 beta Macrophage Inflammatory Protein- 1 beta
  • MIP-3 alpha Macrophage inflammatory protein 3 beta
  • MIP-3 beta Macrophage Migration Inhibitory Factor
  • MSP Malondialdehyde-Modified Low-Density Lipoprotein
  • MDA-LDL Maspin
  • MMP-3 Matrix Metalloproteinase-3
  • MMP-7 Matrix Metalloproteinase-7
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-9 Matrix Metalloproteinase-9
  • MMP-10 Matrix Metalloproteinase- 10
  • MSLN Mesothelin
  • MICA MHC class I chain-related protein A
  • MCP-1 Monocyte Chemotactic Protein 1
  • MCP-2 Monocyte Chemotactic Protein 2
  • MCP-3 Monocyte Chemotactic Protein 3
  • MCP-4 Monocyte Chemotactic Protein 4
  • MIG Monokine Induced by Gamma Interferon
  • MPIF-1 Myeloid Progenitor Inhibitory Factor 1
  • MPO Myeloperoxidase
  • TATI Pancreatic secretory trypsin inhibitor
  • PEPD Peptidase D
  • PECAM-1 Platelet endothelial cell adhesion molecule
  • tPSA Pulmonary surfactant-associated protein D
  • SP-D Pulmonary surfactant-associated protein D
  • TN-X Tenascin-X
  • TSP4 Tissue Inhibitor of Metalloproteinases 2
  • Tissue Inhibitor of Metalloproteinases 2 Tissue Inhibitor of Metalloproteinases 2
  • Tie-1 Tie-1
  • 6Ckine Adiponectin
  • Aldose Reductase Alpha- 1-Antichymotrypsin (AACT), Alpha- 1 -Antitrypsin (AAT), Alpha- 1 -Microglobulin (A 1 Micro), Alpha-2-Macroglobulin (A2Macro), AlphA
  • Thyroxine-B iding Globulin Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), Tissue type Plasminogen activator (tPA), TNF-Related Apoptosis-Inducing Ligand Receptor 3 (TRAIL- R3), Transforming Growth Factor alpha (TGF-alpha), Transforming Growth Factor beta-3 (TGF-beta-3), Transthyretin (TTR), Trefoil Factor 3 (TFF3), Tumor Necrosis Factor alpha (TNF-alpha), Tumor Necrosis Factor beta (TNF-beta), Tumor Necrosis Factor Receptor I (TNF RI), Tumor necrosis factor receptor 2 (TNFR2), Tyrosine kinase with Ig and EGF homology domains 2 (TIE-2), Urokinase-type Plasminogen Activator (uPA), Urokinase-type plasminogen activator receptor (uPAR), Vas
  • VEGF Endothelial Growth Factor
  • VEGF-B Vascular endothelial growth factor B
  • VEGF-C Vascular Endothelial Growth Factor C
  • VEGF-D Vascular endothelial growth factor D
  • VDBP Vitamin D-Binding Protein
  • VKDPS Vitamin K-Dependent Protein S
  • Vitronectin von Willebrand Factor (vWF)
  • vWF von Willebrand Factor
  • Patent G is defined as: Cancer Antigen 19-9, Matrix
  • Metalloproteinase-7 Alpha- 1 -Antichymotryps in, Peptide YY and Apolipoprotein A-I.
  • Porel H is defined as: Matrix Metalloproteinase-7, Pentraxin-3,
  • Panel I is defined as: Cancer Antigen 19-9, Pepsinogen I, Mast/stem cell growth factor receptor, E-Selectin and Total Proinsulin.
  • Panel J is defined as: Pepsinogen I, Interleukin-1 alpha , Mast/stem cell growth factor receptor, Total Proinsulin and Osteopontin.
  • Panel K is defined as: Cancer Antigen 19-9, Alpha- 1-
  • Antichymotrypsin Cathepsin D, Apolipoprotein A-I and 6Ckine.
  • Protein L is defined as: Alpha- 1 -Antichymotrypsin, Cathepsin D,
  • Matrix Metalloproteinase-7, 6Ckine and Mast/stem cell growth factor receptor Matrix Metalloproteinase-7, 6Ckine and Mast/stem cell growth factor receptor.
  • the biomarkers in Panel A (307 biomarkers) were evaluated for their ability ability to discriminate PDAC from healthy control and ChPT.
  • the concentrations of each the biomarkers of Panel A were determined in the plasma of 139 subjects. Plasma samples of 1.0 ml stored in vials were used. Forty seven of the subjects were used as healthy control (CON), forty seven of the subjects were previously diagnosed with chronic pancreatitis (ChPT), and the remaining 42 subjects were previously diagnosed with early stage pancreatic ductal adenocarcinoma (PDAC). Each subject's age and gender were also recorded. The specimens were randomly distributed by disease category across plates and run order to minimize any potential artifacts. Concentrations of the biomarkers were measured in a multiplexed
  • the p-value, q-value, ROC, and mean in group were calculated for each individual analyte using any one of the following methods: t-test, ANOVA, Wilcoxon rank-sum test, rank comparison, Kruskal-Wallis, and/or logistic regression.
  • Logistic regression analyses were carried out on the individual analytes with binary disease category as the dependent variable and analyte, age, and gender as the independent variables.
  • the logistic regression analyses used age- and gender-adjusted analyte values, as described above.
  • the area under the ROC curve was calculated for analytes alone and for the analytes in combination with age and gender using the results of the logistic regression.
  • the false discovery rate q-value is given for each p-value for each analyte.
  • the corresponding values are shown in Megatable 1.
  • the column names, column definitions, values, tests, predictors, response variable, datasets, diseases compared, and formulas have the definitions as outlined in Megatable 2.
  • the column names have the definitions as outlined in Table 1.
  • CON and ChPT versus PDAC identifies 96 analytes (out of 307 total analytes from Panel A) with both p-values less than 0.05 and false discovery rate q-values of 0. 13 or less.
  • 1 19 analytes were identified with p-values less than 0.05 and q-value less than 0. 1.
  • For ChPT versus PDAC 51 analytes were identified with q-value less than 0.29.
  • Table 2 shows the twenty analytes with the lowest p-values for CON and ChPT versus PDAC.
  • Example 1 The data from Example 1 were analyzed with multivariate models to predict disease category. Four modeling methods were used: random forest (rf), boosting, lasso, and logistic regression. The best analytes were selected independently by each of the three modeling methods using estimation of area under the ROC curve (AUC) from 100 bootstraps using the best n variables. These models rank the 15 best biomarkers.
  • rf random forest
  • AUC area under the ROC curve
  • Figures 4- 1 1 illustrate the results of the multivariate analysis.
  • Figures 3-6 illustrate the results of the multivariate analysis including CA 19-9.
  • Figure 3 illustrates PDAC versus CON and ChPT.
  • Figure 4 illustrates PDAC versus CON.
  • Figure 5 illustrates PDAC versus ChPT.
  • Figure 6 illustrates CON versus ChPT.
  • Figures 7- 10 illustrate the results of the multivariate analysis excluding CA 19-9.
  • Figure 7 illustrates PDAC versus CON and ChPT.
  • Figure 8 illustrates PDAC versus CON.
  • Figure 9 illustrates PDAC versus ChPT.
  • Figure 10 illustrates CON versus ChPT.
  • Tables 3- 10 contain the results of the best 15 analytes by each method corresponding to Figures 3 - 10, respectively.
  • Panel A Unique candidate biomarkers were then selected from Panel A to comprise Panel B, Panel C, Panel D, and Panel E.
  • Panel B, Panel C, Panel D, and Panel E comprise: i) the union of: the top analytes from each classification algorithm from the multivariate analysis that excluded CA 19-9, ii) the union of top analytes from univariate analysis, and iii) the union of top analytes from each classification algorithm from multivariate analysis including CA 19-9.
  • Panel B, Panel C, Panel D, and Panel E comprise the biomarkers selected from the analyses of PDAC vs. CON and ChPT, PDAC vs. ChPT, PDAC vs. CON, and CON vs. ChPT, respectively.
  • Megatables 3-5 show panels comprising combinations of 3, 4, or 5 biomarkers for Panel B. Megatable 3 shows combinations of three biomarkers.
  • Megatable 4 shows combinations of four biomarkers.
  • Megatable 5 shows combinations of five biomarkers.
  • Megatables 6-8 show panels comprising combinations of 3, 4, or 5 biomarkers for Panel C. Megatable 6 shows combinations of three biomarkers.
  • Megatable 7 shows combinations of four biomarkers.
  • Megatable 8 shows combinations of five biomarkers.
  • Megatables 9- 1 1 show panels comprising combinations of 3, 4, or 5 biomarkers for Panel D. Megatable 9 shows combinations of three biomarkers.
  • Megatable 10 shows combinations of four biomarkers.
  • Megatable 1 1 shows
  • Megatable 13 shows combinations of four biomarkers. Megatable 14 shows
  • the biomarkers in Panel F (273 biomarkers) were evaluated for their ability to discriminate early, late PDAC, healthy controls and ChPT.
  • the concentration of each of the biomarkers of Panel F was determined in the plasma of 144 additional subjects. Plasma samples of 1.0 mL stored in vials were used. Sixty of the subjects were used as healthy control (CON), 16 of the subjects were previously diagnosed with chronic pancreatitis (ChPT), eight subjects were previously diagnosed with stage IA, IB, IIA PDAC (the early-stage samples), and the remaining 60 subjects were previously diagnosed with stage IIB, III, IV PDAC (the late stage samples). Each subject's age and gender were also recorded. Concentrations of the biomarkers were measured in a multiplexed immunoassay using the RBM MAP platform.
  • ALP Antileukoproteinase
  • E Cad Cadherin 1
  • Cystatin B Lactoferrin
  • LTF Lactoferrin
  • SCFR Mast stem cell growth factor receptor
  • TATI Pancreatic secretory trypsin inhibitor
  • Tissue Inhibitor of Metalloproteinases 2 Tissue Inhibitor of Metalloproteinases 2
  • the raw analyte concentration values were log lO-transformed. These log-transformed values were adjusted by fitting regression models of the form analyte ⁇ age + gender in the control subjects. These regression models were then applied to all subjects (CON, PDAC, and ChPT) and the residuals from this regression were the adjusted analyte values for subsequent analysis. Additionally, age and gender were included in the models to predict disease status.
  • the area under the ROC curve was calculated for analytes alone and for the analytes in combination with age and gender using the results of the logistic regression.
  • the false discovery rate q-value is given for each p-value for each analyte.
  • the corresponding values are shown in Megatable 15.
  • the column names, column definitions, values, tests, predictors, response variable, datasets, diseases compared, and formulas have the definitions as outlined in Megatable 16.
  • Table 13 shows the twenty analytes with the lowest p-values for CON and ChPT versus PDAC for late stages of PDAC.
  • Example 2 The data from Example 2 were analyzed with multivariate models to predict disease category. Three modeling methods were used: random forest (rf), boosting, and lasso. The best analytes were selected independently by each of the three modeling methods using estimation of area under the ROC curve (AUC) from 100 bootstraps using the best n variables. These models rank the 15 best biomarkers.
  • rf random forest
  • AUC area under the ROC curve
  • Figures 13-23 illustrate the results of the multivariate analysis.
  • Figures 13 - 16 illustrate the results of the multivariate analysis using samples representing all stages of PDAC.
  • Figure 13 illustrates PDAC versus CON and ChPT.
  • Figure 14 illustrates PDAC versus CON.
  • Figure 15 illustrates PDAC versus ChPT.
  • Figure 16 illustrates CON versus ChPT.
  • Figures 17-26 illustrate the results of the multivariate analysis using samples representing late stages of PDAC.
  • Figure 17 illustrates PDAC versus CON and ChPT.
  • Figure 18 illustrates PDAC versus CON.
  • Figure 19 illustrates PDAC versus ChPT.
  • Figure 20 illustrates CON versus ChPT.
  • Figures 21 -23 illustrate the results of the multivariate analysis using samples representing early stages of PDAC.
  • Figure 21 illustrates PDAC versus CON and ChPT.
  • Figure 22 illustrates PDAC versus CON.
  • Figure 23 illustrates PDAC versus ChPT.
  • Tables 14-24 contain the results of the analyses by each method corresponding to Figures 13 -23, respectively.
  • Example 1 The results from Example 1 were compared with the results from Example 2.
  • Nine of the analytes in Table 2 are also among the twenty analytes with the lowest p-values in Example 2.
  • Table 25 shows results from Example 2 for the twenty analytes with the lowest p-values for CON and ChPT vs. PDAC.
  • Analytes marked with an asterisk are among the top 20 analytes by p-value in both Example 1 and Example 2. Of these top 20 analytes in Example 2, nine are among the top 20 in Example 1 and 17 of 20 are significant (p ⁇ 0.05) in Example 1.
  • Example 2 was performed based on their analyte values.
  • the analyte values were loglO transformed, age and gender adjusted, and standardized.
  • the cluster dendrogram is illustrated in Figure 25.
  • the resulting tree was divided into 12 clusters.
  • Table 26 shows the counts of disease status in each cluster.
  • Cluster 2 has mostly CON and PDAC, clusters 3 and 4 have mostly PDAC, and cluster 5 is mixed.
  • Embodiment 1 A method of screening for pancreatic cancer, the method comprising: a. determining from a biological sample of a patient the levels of a panel of biomarkers selected from any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both; b. comparing the level of each biomarker to threshold levels for each biomarker; and c. determining the likelihood the patient has pancreatic cancer.
  • Embodiment 2. A method of Embodiment 1 further comprising: a. determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker; and b. conducting endoscopic ultrasonography or magnetic resonance
  • Embodiment 3 The method of Clam 1, further comprising conducting endoscopic ultrasonography or magnetic resonance cholangiopancreatography if the patient has at least 4 biomarkers that have either a level above the threshold level for that particular positive biomarkers or a level below the threshold level for that particular negative biomarkers.
  • Embodiment 4 A method of screening a biological sample, the method comprising: a. obtaining a biological sample; b. determining a level in the biological sample of at least 4 biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both; c. comparing the level of each biomarker to threshold levels for each biomarker; and d. determining the presence or absence of a biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • Embodiment 5 The method of Embodiment 4, further comprising determining a level in the biological sample of each biomarker of the panel.
  • Embodiment 6 The method of Embodiment 4 wherein the levels of the biomarkers in the sample indicate pancreatic cancer.
  • Embodiment 7 A method of screening, the method comprising: a. identifying a patient with (i) a first-degree relative diagnosed with pancreatic cancer, (ii) a mutation in a BRCA2, PALB2, pl6, STK1 1, MLH1, MSH2, MSH6, PMS2, or EPCAM gene, (iii) a diagnosis of hereditary non-polyposis colorectal cancer, or (iv) a diagnosis of Lynch syndrome, Peutz-Jeghers syndrome, acute pancreatitis, chronic pancreatitis, or recent onset diabetes, or (v) a combination of any of the foregoing; b.
  • each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14, wherein the panel comprises positive biomarkers, negative biomarkers, or both; c. comparing the level of each biomarker to threshold levels for each biomarker; and d. determining the presence or absence of a biomarker that either has a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • Embodiment 8 The method of Embodiment 7 wherein determining the presence or absence of a biomarker that either has a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker indicates the presence of pancreatic cancer.
  • Embodiment 9 A method of screening, the method comprising detecting in a biological sample of an individual identified as having (i) a first-degree relative diagnosed with pancreatic cancer, (ii) a mutation in a BRCA2, PALB2, pl6, STK11, MLH1, MSH2, MSH6, PMS2, or EPCAM gene, (iii) a diagnosis of hereditary non-polyposis colorectal cancer, (iv) ) a diagnosis of hereditary non-polyposis colorectal cancer, or (iv) a diagnosis of Lynch syndrome, Peutz- Jeghers syndrome, acute pancreatitis, chronic pancreatitis, or recent onset diabetes or (v) a combination of (i)-(iv), the level of each biomarker of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 10 The method of Embodiment 9 wherein the levels of biomarkers measured indicate the presence of pancreatic cancer.
  • Embodiment 1 A method of screening, the method comprising detecting in a biological sample of an individual identified as having (i) a first-degree relative diagnosed with pancreatic cancer, (ii) a mutation in a BRCA2, PALB2, pi 6, STK11, MLH1, MSH2, MSH6, PMS2, or EPCAM gene, (iii) a diagnosis of hereditary non-polyposis colorectal cancer, (iv) a diagnosis of Lynch syndrome, Peutz-Jeghers syndrome, acute pancreatitis, chronic pancreatitis, or recent onset diabetes or (v) a combination of (i)-(iv), the level of at least 4 biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 12 The method of Embodiment 1 1 wherein the levels of biomarkers measured indicate the presence of pancreatic cancer.
  • Embodiment 13 A method of diagnosing pancreatic cancer, the method comprising:
  • Embodiment 14 The method of Embodiment 13, further comprising determining from the biological sample of the patient a level of each biomarker of the panel.
  • Embodiment 15 The method of Embodiment 13, further comprising determining a number of family members of the patient diagnosed with pancreatic cancer and determining a degree of relationship to the patient of any such family member.
  • Embodiment 16 The method of Embodiment 13, further comprising determining the presence or absence of a mutation in a BRCA2, PALB2, pl6, STKl 1, MLHl, MSH2, MSH6, PMS2, or EPCAM gene of a patient, or determining whether the patient has hereditary non- polyposis colorectal cancer.
  • Embodiment 17 The method of Embodiment 13, wherein the patient has been diagnosed with Koz-Jeghers syndrome, Lynch syndrome, chronic pancreatitis, recent onset diabetes, or acute pancreatitis.
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ultrasonography ultrasonography
  • Retrograde Cholangiopancreatography ERCP
  • Angiography Angiography
  • biopsy Retrograde Cholangiopancreatography
  • Embodiment 19 The method of Embodiment 13, wherein the patient is subsequently treated with surgical resection, ablative techniques, radiation therapy, or chemotherapy.
  • Embodiment 20 The method of Embodiment 13 wherein the biological sample is blood, serum or plasma.
  • Embodiment 21 A method of determining the probability of early-stage pancreatic cancer in a patient, the method comprising: a. determining from a biological sample of a patient a level of each biomarker of a panel of biomarkers for pancreatic cancer, wherein the panel comprises positive biomarkers, negative biomarkers, or both; b. comparing the level of each biomarker to threshold levels for each biomarker; c. determining a number of patient biomarkers that have either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker; and d. calculating a probability of early-stage pancreatic cancer based on the number.
  • Embodiment 22 The method of Embodiment 21, further comprising determining the number of family members of a patient diagnosed with pancreatic cancer and determining a degree of relationship to the patient of any such family member.
  • Embodiment 23 The method of Error! Reference source not found., further comprising determining a magnitude of the difference in level for each biomarker of the patient that is either above a threshold level for that particular positive biomarker or below a threshold level for that particular negative biomarker.
  • Embodiment 24 The method of Embodiment 21, wherein calculating the probability of early-stage pancreatic cancer is further based on a number of family members of the patient diagnosed with pancreatic cancer and the degree of relationship to the patient of any such family member.
  • Embodiment 25 The method of Error! Reference source not found., wherein calculating the probability of early-stage pancreatic cancer is further based on a magnitude of the difference in level for each biomarker of the patient that is either above a threshold level for a positive biomarker or below a threshold level for a negative biomarker.
  • Embodiment 26 The method of Error! Reference source not found., wherein calculating the probability of early-stage pancreatic cancer is also based on a weighted significance of each patient biomarker that has either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker.
  • Embodiment 27 The method of Error! Reference source not found., wherein the panel of biomarkers comprises any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 28 The method of Error! Reference source not found., wherein the panel of biomarkers comprises at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 1 1, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 biomarkers of any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 29 The method of Error! Reference source not found., further comprising determining the presence or absence of a mutation in a BRCA2, PALB2, pl6, STK1 1, MLH1, MSH2, MSH6, PMS2, or EPCAM gene of a patient, or determining whether the patient has hereditary non-polyposis colorectal cancer.
  • Embodiment 30 The method of Error! Reference source not found., wherein calculating the probability of early-stage pancreatic cancer is further based on the presence or absence of a mutation in a BRCA2, PALB2, pl6, STKl 1, MLHl, MSH2, MSH6, PMS2, or EPCAM gene or whether the patient has hereditary non-polyposis colorectal cancer.
  • Embodiment 31 The method of Embodiment 21 , further comprising determining whether the patient is symptomatic of Lynch syndrome, chronic pancreatitis, recent onset diabetes, or acute pancreatitis.
  • Embodiment 32 The method of Error! Reference source not found., wherein calculating the probability of early-stage pancreatic cancer is further based on the patient being symptomatic of Lynch syndrome, chronic pancreatitis, recent onset diabetes, or acute pancreatitis.
  • Embodiment 33 The method of Embodiment 21 , further comprising confirming the probability of early-stage pancreatic cancer by Computed tomography (CT) scan, Somatostatin Receptor Scintigraphy (SRS), Positron Emission Tomography (PET) scan, ultrasonography (ultrasound), Endoscopic Retrograde Cholangiopancreatography (ERCP), Angiography, or biopsy
  • CT Computed tomography
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography or biopsy
  • Embodiment 34 A method of determining a probability of early-stage pancreatic cancer in a patient, the method comprising: a. determining a number of family members of a patient diagnosed with pancreatic cancer and determining a degree of relationship to the patient of any such family member; b. determining the presence or absence of a mutation in a BRCA2, PALB2, pi 6, STKl 1, MLHl, MSH2, MSH6, PMS2, or EPCAM gene of a patient, or determining whether the patient has hereditary non-polyposis colorectal cancer; c.
  • calculating a probability of early-stage pancreatic cancer based on at least (i) the number of family members of the patient diagnosed with pancreatic cancer, (ii) the degree of relationship to the patient of any such family member, (iii) the presence or absence of a mutation in a BRCA2, PALB2, pl6, STK1 1, MLH1, MSH2, MSH6, PMS2, or EPCAM gene or whether the patient has hereditary non-polyposis colorectal cancer, (iv) the number of patient biomarkers that have either a level above the threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker, and (v) the magnitude of the difference in level for each biomarker of the patient that is either above the threshold level for that particular positive biomarkers or below the threshold level for that particular negative biomarkers.
  • Embodiment 35 A computer-assisted method of determining a probability of a patient having early-stage pancreatic cancer, the method comprising: a. providing biomarker information from a biomarker information database module on a data processing device, wherein the biomarker information comprises threshold level information for each biomarker of a panel of biomarkers, wherein the panel of biomarkers comprises positive biomarkers, negative biomarkers, or both, wherein a level above the threshold level for each particular positive biomarkers is indicative of the presence of pancreatic cancer in a patient and a level below the threshold level for each particular negative biomarkers is indicative of the presence of pancreatic cancer in a patient; b.
  • patient information from a patient information database module on a data processing device, wherein the patient information comprises biomarker level information for the patient; c. comparing with a comparison module on a data processing device biomarker information and patient information; d. determining with an evaluation module on a data processing device operably connected to the comparison module a number of patient biomarkers with either a level above a threshold level for each particular positive biomarker or a level below a threshold level for each particular negative biomarker; and e. determining with a calculation module on a data processing device operably
  • Embodiment 36 The method of Error! Reference source not found., further comprising providing to the calculation module family history information from a family history database module on a data processing device, the family history information comprising a number of family members of the patient diagnosed with pancreatic cancer, and wherein determining a probability of early-stage pancreatic cancer is further based on the number of family members of the patient diagnosed with pancreatic cancer.
  • Embodiment 37 The method of Error! Reference source not found., wherein the family history information comprises a degree of relationship to the patient of each family member diagnosed with pancreatic cancer.
  • Embodiment 38 The method of Embodiment 36, wherein the family history database comprises a patient file history database.
  • Embodiment 39 The method of Error! Reference source not found., wherein the patient information database comprises a patient file history database.
  • Embodiment 40 The method of Embodiment 36, further comprising displaying a graphical presentation of the patient's probability of early-stage pancreatic cancer with a display operably connected to the calculation module.
  • Embodiment 41 The method of Embodiment 36, further comprising determining additional suggested diagnostic procedures based on the patient's probability of early-stage pancreatic cancer with a diagnostic module operably connected to the calculation module.
  • Embodiment 42 The method of Embodiment 36, wherein the panel of biomarkers comprises any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 43 A kit for detecting the presence of early-stage pancreatic cancer in a patient, the kit comprising reagents useful, sufficient, or necessary for determining the level of at least three biomarkers in any one of Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 44 A method of assessing the likelihood pancreatic cancer in a patient, comprising: a. obtaining a biological sample from a patient b. assaying the biological sample to determine the levels of a panel of at least three biomarkers in the biological sample, c. comparing the levels of the biomarkers to a threshold for each biomarker, where some biomarkers are positively associated with pancreatic cancer, and some biomarkers are negatively associated with pancreatic cancer d. determining the levels of the biomarkers in the biological sample are above the threshold for biomarkers that are positively associated with pancreatic cancer or below the threshold for biomarkers that are negatively associated with pancreatic cancer; and e. determining the likelihood the patient has pancreatic cancer.
  • Embodiment 45 The method of Embodiment 44 wherein the threshold value for each biomarker is determined by measuring the level of each biomarker in control subjects.
  • Embodiment 46 The method of Embodiment 45 wherein the control subjects are healthy and age- and sex- matched.
  • Embodiment 47 The method of Embodiment 45 wherein the levels of the biomarkers in the subject are further compared to the levels of biomarkers in subjects who have a diagnosis of diabetes, or non-pancreatic cancer.
  • Embodiment 48 The method of Embodiment 45 wherein the threshold value for each biomarker is determined by measuring the level of each biomarker in subject with a known early stage pancreatic cancer diagnosis.
  • Embodiment 49 The method of Embodiment 45 wherein the biomarkers are selected from Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 50 The method of Embodiment 45 wherein the biomarkers are any 3, 4, 5, 6, 7, 8, 9, or 10 of the biomarkers listed in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 51 The method of Embodiment 45 wherein determining the likelihood of pancreatic cancer is further supported by biopsy, Computed tomography (CT) scan, Somatostatin Receptor Scintigraphy (SRS), Positron Emission Tomography (PET) scan, ultrasonography (ultrasound), Endoscopic Retrograde Cholangiopancreatography (ERCP), or Angiography.
  • CT Computed tomography
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography Angiography
  • Embodiment 52 The method of Embodiment 44 where in the patient has (i) a first-degree relative diagnosed with pancreatic cancer, (ii) a mutation in a BRCA2, PALB2, pl6, STK1 1, MLHl, MSH2, MSH6, PMS2, or EPCAM gene, (iii) a diagnosis of hereditary non-polyposis colorectal cancer, (iv) a diagnosis of Lynch syndrome, Peutz-Jeghers syndrome, acute pancreatitis, chronic pancreatitis, or recent onset diabetes or (v) a combination of (i)-(iv).
  • Embodiment 53 The method of Embodiment 44 wherein the levels of the at least three biomarkers indicates an early stage pancreatic cancer diagnosis.
  • Embodiment 54 The method of embodiment 44 wherein the levels of the at least three biomarkers indicates a diagnosis of stage 1, 2, or 3 pancreatic cancer.
  • Embodiment 55 The method of Embodiment 44 wherein the patient is treated for pancreatic cancer through surgical resection, chemotherapy, drug therapy, or radiation therapy.
  • Embodiment 56 The method of Embodiment 44 wherein the sample is blood, serum or plasma.
  • Embodiment 57 A method of assessing the likelihood of pancreatic cancer in a subject comprising: a. obtaining a biological sample from a subject b. obtaining a biological sample from a control subject or group of control subjects c. measuring the levels a panel of at least three biomarkers in the subject and control subject or control subjects d. comparing the levels of biomarkers in the subject and control subject(s) and e. determining the likelihood of pancreatic cancer in the subject based at least in part on the difference in the levels of the at least three biomarkers in the subject compared to the control subject(s)
  • Embodiment 58 The method of embodiment 57 wherein the subject is human.
  • Embodiment 59 The method of embodiment 57 wherein biological sample is blood, serum or plasma.
  • Embodiment 60 The method of embodiment 57 wherein the control subjects are healthy age matched individuals.
  • Embodiment 61 The method of embodiment 57 wherein the control subjects have a diagnosis of non-pancreatic cancer, or diabetes.
  • Embodiment 62 The method of embodiment 57 wherein the subject is symptomatic of Lynch syndrome, chronic pancreatitis, acute pancreatitis, recent onset diabetes, or 22, Zaz-Jeghers syndrome.
  • Embodiment 63 The method of embodiment 57 wherein the subject has at least one first- degree relative who has been diagnosed with pancreatic cancer.
  • Embodiment 64 The method of embodiment 57 wherein the subject has a mutation in the pl6, BRCA2, PALB2, or STK11 genes.
  • Embodiment 65 The method of embodiment 57 wherein biomarkers are selected from any panel A through L.
  • Embodiment 66 The method of embodiment 57 wherein the biomarkers are selected from biomarkers in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14 with a t-test p-value equal to or less than 0.05.
  • Embodiment 67 The method of embodiment 57 wherein the biomarkers are selected from biomarkers in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14 with an ANOVA p-value equal to or less than 0.05.
  • Embodiment 68 The method of embodiment 57 wherein the biomarkers are selected from biomarkers in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14 with a Wilcoxon rank sum p-value equal to or less than 0.05.
  • Embodiment 69 The method of embodiment 57 wherein the biomarkers are selected from biomarkers in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14 with a Kruskal-Wallis p-value equal to or less than 0.05.
  • Embodiment 70 The method of embodiment 57 wherein pancreatic cancer in the subject is confirmed by biopsy, Computed tomography (CT) scan, Somatostatin Receptor Scintigraphy (SRS), Positron Emission Tomography (PET) scan, ultrasonography (ultrasound), Endoscopic Retrograde Cholangiopancreatography (ERCP), or Angiography.
  • CT Computed tomography
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography Angiography
  • Embodiment 71 The method of embodiment 57 wherein the patient is treated by chemotherapy, radiation therapy, or ablative techniques.
  • Embodiment 72 The method of embodiment 57 wherein said determination of pancreatic cancer is computed by a system where the levels of three or more biomarkers are related to a numerical value, comparing the numerical value with a numerical index database and analyzing whether said numerical index falls within a range of database index results that is predetermined to be indicative of pancreatic cancer.
  • Embodiment 73 The method of embodiment 57 wherein the results of said comparison are provided in a report.
  • Embodiment 74 A method of treating a patient comprising:
  • Embodiment 75 A method of treating pancreatic cancer in a subject comprising: a. obtaining a biological sample from a subject; b. measuring the levels of a panel of at least three biomarkers in the biological sample; c. comparing the levels of the biomarkers in the subject to a threshold; d. diagnosing the patient with pancreatic cancer; and e. treating the patient for pancreatic cancer.
  • Embodiment 76 The method of embodiment 75 wherein the biological sample is blood, serum or plasma.
  • Embodiment 77 The method of embodiment 75 wherein the diagnosis of pancreatic cancer is based at least in part on the difference between the biomarker levels in the patient and the threshold level.
  • Embodiment 78 The method of embodiment 75 wherein the threshold level is determined by measuring the levels of the at least three biomarkers in a control sample.
  • Embodiment 79 The method of embodiment 78 wherein the control sample is from a healthy, age matched individual or group of individuals.
  • Embodiment 80 The method of embodiment 78 wherein the threshold level is further determined by measuring the levels of the at least three biomarkers in samples from individuals with a non-pancreatic cancer diagnosis.
  • Embodiment 81 The method of embodiment 78 wherein the threshold level is further determined by measuring the levels of the at least three biomarkers in samples from individuals diagnosed with diabetes.
  • Embodiment 82 The method of embodiment 78 wherein the threshold level is further determined by measuring the levels of the at least three biomarkers in samples from individuals with early stage pancreatic cancer diagnosis.
  • Embodiment 83 The method of embodiment 75 wherein the biomarkers are selected from any biomarkers listed in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 84 The method of embodiment 75 wherein the patient has at least one first degree relative with a pancreatic cancer diagnosis
  • Embodiment 85 The method of embodiment 75 wherein the patient is symptomatic of Lynch syndrome, chronic pancreatitis, new onset diabetes, acute pancreatitis, or Peutz-Jeghers syndrome.
  • Embodiment 86 The method of embodiment 75 wherein the patient has a germ-line mutation in the pi 6, BRCA2, PALB2, or STK11 genes.
  • Embodiment 87 The method of embodiment 75 wherein the pancreatic cancer diagnosis is confirmed by biopsy, Computed tomography (CT) scan, Somatostatin Receptor Scintigraphy (SRS), Positron Emission Tomography (PET) scan, ultrasonography (ultrasound), Endoscopic Retrograde Cholangiopancreatography (ERCP), or Angiography.
  • CT Computed tomography
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography Angiography
  • Embodiment 88 The method of embodiment 75 wherein the treatment for pancreatic cancer is chemotherapy, radiation therapy, or ablative techniques.
  • Embodiment 89 A method for diagnosing pancreatic cancer in a subject, the method comprising: a. contacting a biological sample from the subject with at least three reagents, each one of which specifically binds to a different biomarker in a panel b. determining whether the selected marker is over expressed or under expressed in the sample, thereby providing a diagnosis for pancreatic cancer in the subject.
  • Embodiment 90 The method of embodiment 89 wherein the over or under expression is determined by comparing expression level to a predetermined threshold.
  • Embodiment 91 The method of embodiment 89 wherein the over or under expression of the panel of biomarkers is determined by comparing the levels in the patient to a control group.
  • Embodiment 92 The method of embodiment 91 wherein the control group is made up of healthy age-matched individuals.
  • Embodiment 94 The method of embodiment 89 wherein the subject has been diagnosed with or is symptomatic of Lynch syndrome, chronic pancreatitis, new onset diabetes, acute pancreatitis, or Peutz-Jeghers syndrome.
  • Embodiment 95 The method of embodiment 89 wherein the subject has at least one first degree relative with a pancreatic cancer diagnosis.
  • Embodiment 96 The method of embodiment 89 where in the subject has a germ line germ- line mutation in at least one of the pi 6, BRCA2, PALB2, or STK11 genes.
  • Embodiment 97 The method of embodiment 89 wherein the biological sample is blood, serum or plasma.
  • Embodiment 98 The method of embodiment 89 wherein determining an expression level comprises determining protein expression.
  • Embodiment 99 The method of embodiment 89, wherein the subject is at risk for developing pancreatic cancer.
  • Embodiment 100 A method of classifying a patient at risk for pancreatic cancer, comprising: a. determining a level of at least three of the biomarkers in a sample obtained from a subject; b. comparing the levels the at least three biomarkers to a cut-off value, wherein the cut-off value was determined by analysis of normalized expression values for the at least three biomarkers in a panel of control samples; c. and characterizing the patient as having a low likelihood of pancreatic cancer if the measured levels of biomarkers are on the same side of the cut-off value as the panel of control samples or characterizing the patient as having a high likelihood of pancreatic cancer if the output value is on the opposite side of the cut-off value as the panel of control samples.
  • Embodiment 101 A method of determining the likelihood of pancreatic cancer in a patient, comprising: a. determining, in a sample obtained from the patient, an expression level of at least three biomarkers selected from any listed in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14; b. calculating an output from an algorithm that uses the expression levels of the at least three biomarkers as an input; and c. determining from the algorithm output that the patient has or does not have
  • pancreatic cancer by comparing the output to a reference standard from control samples.
  • Embodiment 102 The method of embodiment 101 wherein the levels of biomarkers in the subject are additionally compared to the output to a reference standard from samples from individuals with a pancreatic cancer diagnosis.
  • Embodiment 103 The method of embodiment 101 wherein the steps of calculating the output from the algorithm, and determining from the algorithm output that the sample is or is not malignant by comparing the output to a reference standard are performed by a suitably programmed computer.
  • Embodiment 104 The method of embodiment 101, further comprising providing to a user a report comprising the algorithm output or the determination that the patient has a high or low likelihood of having pancreatic cancer.
  • Embodiment 105 The method of embodiment 101, wherein if the patient is determined as having a high likelihood of pancreatic cancer, the method further comprises selecting the subject for treatment for pancreatic cancer.
  • Embodiment 106 The method of embodiment 101, further comprising treating the subject for pancreatic cancer.
  • Embodiment 107 The method of embodiment 101, wherein the patient is determined to have a high likelihood of early stage pancreatic cancer.
  • Embodiment 108 The method of embodiment 101 wherein the patient the algorithm incorporates the patient's family history, and personal medical history into the determination of likelihood of pancreatic cancer.
  • Embodiment 109 A method of treating pancreatic cancer comprising a. assaying a biological sample from a patient to determine the levels of a panel of biomarkers in the biological sample; b. determining that the levels of a panel of biomarkers is increased or decreased relative to a reference standard; c. administering to said patient, therapy based on the levels of a panel of biomarkers;
  • Embodiment 1 10. The method of embodiment 103 wherein the panel of biomarkers comprises three or more of Panel A.
  • Embodiment 1 11. The method of embodiment 103 wherein the panel of biomarkers comprises at least three biomarkers selected from those listed in Panels A through L, or any panel of 3, 4, or 5 biomarkers in Megatables 3 through 14.
  • Embodiment 1 A method of determining and increased likelihood of pancreatic cancer in an individual, comprising a. assaying a tissue sample from the individual by multiplexed immunoassay to determined the normalized levels of a panel of biomarkers;
  • Embodiment 1 14. The method of claim 1, wherein the statistical model is generated using the normalized levels of the panel of biomarkers in a population comprising healthy individuals and individuals with pancreatic cancer.
  • Embodiment 1 15. The method of claim 1, wherein the tissue sample is blood, plasma or serum.
  • Embodiment 1 16. The method of claim 1, wherein the increased liekelihood of pancreatic cancer is confirmed by Computed tomography (CT) scan, Somatostatin Receptor Scintigraphy (SRS), Positron Emission Tomography (PET) scan, ultrasonography (ultrasound), Endoscopic Retrograde Cholangiopancreatography (ERCP), Angiography, or biopsy.
  • CT Computed tomography
  • SRS Somatostatin Receptor Scintigraphy
  • PET Positron Emission Tomography
  • ERCP Endoscopic Retrograde Cholangiopancreatography
  • Angiography or biopsy.
  • Embodiment 1 17. The method of claim 1, wherein the pancreatic cancer is early stage cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés de diagnostic et, en particulier, des biomarqueurs permettant de diagnostiquer un cancer du pancréas et des procédés d'utilisation de ceux-ci.
PCT/US2015/025179 2014-04-09 2015-04-09 Procédés de diagnostic du cancer du pancréas et procédés associés WO2015157557A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977574P 2014-04-09 2014-04-09
US61/977,574 2014-04-09

Publications (1)

Publication Number Publication Date
WO2015157557A1 true WO2015157557A1 (fr) 2015-10-15

Family

ID=53005690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/025179 WO2015157557A1 (fr) 2014-04-09 2015-04-09 Procédés de diagnostic du cancer du pancréas et procédés associés

Country Status (1)

Country Link
WO (1) WO2015157557A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110441438A (zh) * 2019-09-09 2019-11-12 大连医科大学附属第一医院 一种基于s100蛋白家族的急性胰腺炎严重程度预测模型及其检测方法
WO2020169511A1 (fr) 2019-02-18 2020-08-27 The University Of Liverpool Procédé de diagnostic
CN112176057A (zh) * 2020-09-23 2021-01-05 中国人民解放军海军军医大学第一附属医院 利用CpG位点甲基化水平检测胰腺导管腺癌的标志物及其应用
WO2021006649A1 (fr) * 2019-07-09 2021-01-14 주식회사 베르티스 Panel de biomarqueurs pour le diagnostic du cancer du pancréas et utilisation de celui-ci
WO2021076036A1 (fr) * 2019-10-18 2021-04-22 Reccan Diagnostics Ab Appareils et procédés pour la détection du cancer du pancréas
US11320436B2 (en) 2020-07-16 2022-05-03 Immunovia Ab Methods, arrays and uses thereof
US11525832B2 (en) 2007-03-27 2022-12-13 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FRIESS H ET AL: "PANCREARTIC CANCER: THE POTENTIAL CLINICAL RELEVANCE OF ALTERATIONSIN GROWTH FACTORS AND THEIR RECEPTORS", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 74, 1 January 1996 (1996-01-01), pages 35 - 42, XP002939259, ISSN: 0946-2716, DOI: 10.1007/BF00202070 *
HYUNG-DOO PARK ET AL: "Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma", PROTEOMICS, vol. 12, no. 23-24, 1 December 2012 (2012-12-01), pages 3590 - 3597, XP055194992, ISSN: 1615-9853, DOI: 10.1002/pmic.201200101 *
IRENE ESPOSITO ET AL: "The Stem Cell Factor-c-kit System and Mast Cells in Human Pancreatic Cancer", LABORATORY INVESTIGATION, vol. 82, no. 11, 1 November 2002 (2002-11-01), pages 1481 - 1492, XP055194998, ISSN: 0023-6837, DOI: 10.1097/01.LAB.0000036875.21209.F9 *
R. E. BRAND ET AL: "Serum Biomarker Panels for the Detection of Pancreatic Cancer", CLINICAL CANCER RESEARCH, vol. 17, no. 4, 15 February 2011 (2011-02-15), pages 805 - 816, XP055195019, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-0248 *
REBECCA SIEGEL ET AL.: "Cancer Statistics", CA: A CANCER JOURNAL FOR CLINICIANS, vol. 11, 2013
S KONDO ET AL: "Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma", BRITISH JOURNAL OF CANCER, vol. 109, no. 3, 4 July 2013 (2013-07-04), pages 739 - 746, XP055194996, ISSN: 0007-0920, DOI: 10.1038/bjc.2013.348 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11525832B2 (en) 2007-03-27 2022-12-13 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
WO2020169511A1 (fr) 2019-02-18 2020-08-27 The University Of Liverpool Procédé de diagnostic
WO2021006649A1 (fr) * 2019-07-09 2021-01-14 주식회사 베르티스 Panel de biomarqueurs pour le diagnostic du cancer du pancréas et utilisation de celui-ci
CN110441438A (zh) * 2019-09-09 2019-11-12 大连医科大学附属第一医院 一种基于s100蛋白家族的急性胰腺炎严重程度预测模型及其检测方法
WO2021076036A1 (fr) * 2019-10-18 2021-04-22 Reccan Diagnostics Ab Appareils et procédés pour la détection du cancer du pancréas
US11320436B2 (en) 2020-07-16 2022-05-03 Immunovia Ab Methods, arrays and uses thereof
CN112176057A (zh) * 2020-09-23 2021-01-05 中国人民解放军海军军医大学第一附属医院 利用CpG位点甲基化水平检测胰腺导管腺癌的标志物及其应用
CN112176057B (zh) * 2020-09-23 2023-11-10 中国人民解放军海军军医大学第一附属医院 利用CpG位点甲基化水平检测胰腺导管腺癌的标志物及其应用

Similar Documents

Publication Publication Date Title
WO2015157557A1 (fr) Procédés de diagnostic du cancer du pancréas et procédés associés
Kupcova Skalnikova et al. Advances in proteomic techniques for cytokine analysis: focus on melanoma research
Rho et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer
Yu et al. Protein microarrays for personalized medicine
US20210398682A1 (en) Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof
EP2831586B1 (fr) Dispositif et procédé pour la détection d'analysats
US10684292B2 (en) Methods for detection of emphysema
US20160011214A1 (en) Quantitative diagnostic methods using multiple parameters
US20110251099A1 (en) SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Rižner Diagnostic potential of peritoneal fluid biomarkers of endometriosis
US8772038B2 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
EP3443125B1 (fr) Méthodes d'évaluation de l'activité d'une sclérose en plaques
JP2009501318A (ja) アテローム動脈硬化性心血管疾患の診断およびモニタリングのための方法ならびに組成物
Wang et al. Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer
WO2010033838A1 (fr) Dosages de molécule unique
KR20100062996A (ko) 난소암의 예측 마커
JP2022000650A (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット
US20120178100A1 (en) Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis
WO2015082927A1 (fr) Panel de nouveaux biomarqueurs pour dépressions majeures
CN114730613A (zh) 用于预测多发性硬化症疾病活动的生物标志物
US20190331683A1 (en) Biomarkers of Rapid Progression in Advanced Non-Small Cell Lung Cancer
Shi et al. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis
WO2015193427A1 (fr) Détermination et analyse de biomarqueurs dans des échantillons cliniques.
Bellocchi et al. Large‐Scale characterization of systemic sclerosis serum protein profile: comparison to peripheral blood cell transcriptome and correlations with Skin/Lung fibrosis
Zhang et al. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15718711

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15718711

Country of ref document: EP

Kind code of ref document: A1